LY2334737|cas 892128-60-8|DC Chemicals
LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.
Product Name: LY2334737|Cat No. DC9304|cas: 892128-60-8|Other names: LY 2334737,LY-2334737,LY2334737| Molecule formular: C17H25F2N3O5Molecule Weight: 389.39
LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.
IC50 Value:
in vitro: Five cell lines that express CES2 responded to LY2334737treatment. LY2334737 was less cytotoxic to a SK-OV-3 CES2 knockdown than parental cells. The drug response of CES2-transfected HCT-116 cells correlated with CES2 expression level. Bystander studies showed statistically greater PC-3-GFP growth inhibition by LY2334737 when cells were cocultured with CES2 and not mock transfectants.
in vivo: Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001). The MTD was 40 mg LY2334737. Fatigue was the most frequent DLT for LY2334737monotherapy (4 patients) followed by elevated transaminase levels (2 patients), both observed at the 40- to 50-mg dose levels. Among the 10 patients in the combination arm, 2 had DLTs at the 40-mg dose level. These were fatigue and elevated liver enzyme levels. Metronomic LY2334737 administration caused increased blood flow in luciferase-tagged LM2-4 tumor xenografts, and this effect, readily measured using contrast micro-ultrasound, coincided with a relative increase in tumor bioluminescence.
2016年5月23日星期一
CP-544326|cas 752187-80-7|DC Chemicals
CP-544326|cas 752187-80-7|DC Chemicals
CP-544326 is a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Product Name: CP-544326|Cat No. DC9303|cas: 752187-80-7|Other names: CP-544326;CP544326;CP 544326| Molecule formular: C24H22N4O5SMolecule Weight: 478.52
CP-544326 is a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
CP-544326 is a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Product Name: CP-544326|Cat No. DC9303|cas: 752187-80-7|Other names: CP-544326;CP544326;CP 544326| Molecule formular: C24H22N4O5SMolecule Weight: 478.52
CP-544326 is a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
MLN 2480(BIIB-024)|cas 1096708-71-2|DC Chemicals
MLN 2480(BIIB-024)|cas 1096708-71-2|DC Chemicals
MLN 2480(BIIB-024) is an oral, selective pan-Raf kinase inhibitor in chinical trials.
Product Name: MLN 2480(BIIB-024)|Cat No. DC9302|cas: 1096708-71-2|Other names: BIIB-024; MLN2480; MLN-2480| Molecule formular: C17H12Cl2F3N7O2SMolecule Weight: 506.29
in vitro: MLN-2480 is active against wild-type B-raf and B-raf Val600Glu in vitro. MLN-2480 is found to activate phosphorylated MEK at very low concentrations, but at higher concentrations MLN-2480 inhibits this same activity. MLN-2480 inhibits signaling pathway at high concentrations in the human malignant melanoma A-375 mutant B-raf Val600Glu cell line. The inhibitory effects of MLN-2480 are found to vary across models and genetic contexts; MLN-2480 only modestly inhibits PRAK. MLN-2480 in combination with TAK-733 demonstrates synergy in NRAS mutant human malignant melanoma cell lines (SK-MEL-2), with high levels of apoptotic biomarkers observed.
in vivo: MLN-2480 (37.5 mg/kg) is well tolerated in a tumor xenograft model. The combination of MLN-2480 (12.5 mg) and TAK-733 (1 mg/kg) is effective in an SK-MEL-30 xenograft model, but monotherapy with either compound produced negligible effects.
MLN 2480(BIIB-024) is an oral, selective pan-Raf kinase inhibitor in chinical trials.
Product Name: MLN 2480(BIIB-024)|Cat No. DC9302|cas: 1096708-71-2|Other names: BIIB-024; MLN2480; MLN-2480| Molecule formular: C17H12Cl2F3N7O2SMolecule Weight: 506.29
in vitro: MLN-2480 is active against wild-type B-raf and B-raf Val600Glu in vitro. MLN-2480 is found to activate phosphorylated MEK at very low concentrations, but at higher concentrations MLN-2480 inhibits this same activity. MLN-2480 inhibits signaling pathway at high concentrations in the human malignant melanoma A-375 mutant B-raf Val600Glu cell line. The inhibitory effects of MLN-2480 are found to vary across models and genetic contexts; MLN-2480 only modestly inhibits PRAK. MLN-2480 in combination with TAK-733 demonstrates synergy in NRAS mutant human malignant melanoma cell lines (SK-MEL-2), with high levels of apoptotic biomarkers observed.
in vivo: MLN-2480 (37.5 mg/kg) is well tolerated in a tumor xenograft model. The combination of MLN-2480 (12.5 mg) and TAK-733 (1 mg/kg) is effective in an SK-MEL-30 xenograft model, but monotherapy with either compound produced negligible effects.
TA-01|TA01|DC Chemicals
TA-01|TA01|DC Chemicals
TA-01 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction at 1 μM. Inhibits cardiomyocyte differentiation at 5 μM. Potently inhibits CK1ε, p38α, and CK1δ (IC50 values are 6.4, 6.7 and 6.8 nM respectively)..
Product Name: TA-01|Cat No. DC9301|cas: N/A|Other names: TA-01,TA01，TA 01| Molecule formular: C20H12F3N3Molecule Weight: 351.32
TA-01 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction at 1 μM. Inhibits cardiomyocyte differentiation at 5 μM. Potently inhibits CK1ε, p38α, and CK1δ (IC50 values are 6.4, 6.7 and 6.8 nM respectively).
TA-01 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction at 1 μM. Inhibits cardiomyocyte differentiation at 5 μM. Potently inhibits CK1ε, p38α, and CK1δ (IC50 values are 6.4, 6.7 and 6.8 nM respectively)..
Product Name: TA-01|Cat No. DC9301|cas: N/A|Other names: TA-01,TA01，TA 01| Molecule formular: C20H12F3N3Molecule Weight: 351.32
TA-01 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction at 1 μM. Inhibits cardiomyocyte differentiation at 5 μM. Potently inhibits CK1ε, p38α, and CK1δ (IC50 values are 6.4, 6.7 and 6.8 nM respectively).
TA-02|TA02|DC Chemicals
TA-02|TA02|DC Chemicals
TA-02 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction. Potently inhibits p38α, CK1δ and CK1ε (IC50 values are 20, 32 and 32 nM respectively).
Product Name: TA-02|Cat No. DC9300|cas: N/A|Other names: TA-02,TA02，TA 02| Molecule formular: C20H13F2N3Molecule Weight: 333.33
TA-02 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction. Potently inhibits p38α, CK1δ and CK1ε (IC50 values are 20, 32 and 32 nM respectively).
TA-02 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction. Potently inhibits p38α, CK1δ and CK1ε (IC50 values are 20, 32 and 32 nM respectively).
Product Name: TA-02|Cat No. DC9300|cas: N/A|Other names: TA-02,TA02，TA 02| Molecule formular: C20H13F2N3Molecule Weight: 333.33
TA-02 induces cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction. Potently inhibits p38α, CK1δ and CK1ε (IC50 values are 20, 32 and 32 nM respectively).
GRA Ex-25 |CAS 307983-31-9|DC Chemicals
GRA Ex-25 |CAS 307983-31-9|DC Chemicals
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk.
Product Name: GRA Ex-25|Cat No. DC9299|cas: 307983-31-9|Other names: | Molecule formular: C29H36F3N3O5Molecule Weight: 563.61
GRA Ex-25(compound 15) is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. GRA Ex-25 is orally bioavailable in several preclinical species and shows selectivity toward cardiac ion channels and other family B receptors, such as hGIP1 and hGLP.
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk.
Product Name: GRA Ex-25|Cat No. DC9299|cas: 307983-31-9|Other names: | Molecule formular: C29H36F3N3O5Molecule Weight: 563.61
GRA Ex-25(compound 15) is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. GRA Ex-25 is orally bioavailable in several preclinical species and shows selectivity toward cardiac ion channels and other family B receptors, such as hGIP1 and hGLP.
thiotepa|CAS 52-24-4| DC Chemicals
thiotepa|CAS 52-24-4| DC Chemicals
N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group.
Product Name: thiotepa|Cat No. DC9298|cas: 52-24-4|Other names: | Molecule formular: C6H12N3PSMolecule Weight: 189.21
N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group.
Product Name: thiotepa|Cat No. DC9298|cas: 52-24-4|Other names: | Molecule formular: C6H12N3PSMolecule Weight: 189.21
Orexin-2 receptor agonist|cas 1796565-52-0
Orexin-2 receptor agonist|cas 1796565-52-0
Orexin-2 receptor agonist the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%)
Product Name: Orexin-2 receptor agonist|Cat No. DC9297|cas: 1796565-52-0|Other names: Orexin-2 receptor agonist,Orexin2 receptor agonist,OX2R agonist| Molecule formular: C32H34N4O5SMolecule Weight: 586.7
Orexin-2 receptor agonist the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%)
Orexin-2 receptor agonist the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%)
Product Name: Orexin-2 receptor agonist|Cat No. DC9297|cas: 1796565-52-0|Other names: Orexin-2 receptor agonist,Orexin2 receptor agonist,OX2R agonist| Molecule formular: C32H34N4O5SMolecule Weight: 586.7
Orexin-2 receptor agonist the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%)
A-1331852|CAS 1430844-80-6|DC Chemicals
A-1331852|CAS 1430844-80-6|DC Chemicals
A-1331852 is a high affinity BH3 mimetic Ligand of BCL protein BCL-XL.
Product Name: A-1331852|Cat No. DC9296|cas: 1430844-80-6|Other names: A 1331852,A1331852| Molecule formular: C38H38N6O3SMolecule Weight: 658.81
A-1331852 is a high affinity BH3 mimetic Ligand of BCL protein BCL-XL.
Product Name: A-1331852|Cat No. DC9296|cas: 1430844-80-6|Other names: A 1331852,A1331852| Molecule formular: C38H38N6O3SMolecule Weight: 658.81
Elbasvir(MK-8742)|CAS 1370468-36-2|DC Chemicals
Elbasvir(MK-8742)|CAS 1370468-36-2|DC Chemicals
Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
Product Name: Elbasvir(MK-8742)|Cat No. DC9295|cas: 1370468-36-2|Other names: MK-8742; MK8742; MK 8742| Molecule formular: C49H55N9O7Molecule Weight: 882.02
Elbasvir possesses activity against genotype 1a, 1b, and 3 in vitro, including against some viral variants resistant to other NS5A inhibitors. In a phase 1b dose escalation study, Elbasvir once daily for 5 days resulted in mean reductions in HCV RNA levels of 3.7 to 5.1 log10IU/ml in patients with genotype 1a or 1b infections given 5 to 50 mg/day and of 3 log10 IU/ml in patients with genotype 3 given 50 or 100 mg/day. In later phase 2 trials, treatment with Elbasvir combined with Grazoprevir (MK-5172, an investigational once-daily NS3/4A protease inhibitor) with or without Ribavirin for 12 weeks produced rates of sustained virological response at week 12 (SVR12) of 87 to 98% for patients with genotype 1 infections, including in historically difficult-to-treat subgroups.
For research and scientific purpose only, not for human use!
Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
Product Name: Elbasvir(MK-8742)|Cat No. DC9295|cas: 1370468-36-2|Other names: MK-8742; MK8742; MK 8742| Molecule formular: C49H55N9O7Molecule Weight: 882.02
Elbasvir possesses activity against genotype 1a, 1b, and 3 in vitro, including against some viral variants resistant to other NS5A inhibitors. In a phase 1b dose escalation study, Elbasvir once daily for 5 days resulted in mean reductions in HCV RNA levels of 3.7 to 5.1 log10IU/ml in patients with genotype 1a or 1b infections given 5 to 50 mg/day and of 3 log10 IU/ml in patients with genotype 3 given 50 or 100 mg/day. In later phase 2 trials, treatment with Elbasvir combined with Grazoprevir (MK-5172, an investigational once-daily NS3/4A protease inhibitor) with or without Ribavirin for 12 weeks produced rates of sustained virological response at week 12 (SVR12) of 87 to 98% for patients with genotype 1 infections, including in historically difficult-to-treat subgroups.
For research and scientific purpose only, not for human use!
Tenofovir Alafenamide Hemifumarate|DC Chemicals
Tenofovir Alafenamide Hemifumarate|DC Chemicals
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate.
Product Name: Tenofovir Alafenamide Hemifumarate|Cat No. DC9294|cas: 1392275-56-7|Other names: Tenofovir alafenamide; GS7340; GS 7340| Molecule formular: C46H62N12O14P2Molecule Weight: 1068.4
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate.
IC50 value:
Target: NRTI; HIV reverse transcriptase inhibitor
GS-7340 reduces first-pass clearance to be an effective oral prodrug, its permeability and stability were characterized in vitro and detailed pharmacokinetic studies were completed in dogs. GS-7340 showed concentration-dependent permeability through monolayers of caco-2 cells and dose-dependent oral bioavailability in dogs, increasing from 1.7% at 2 mg/kg to 24.7% at 20 mg/kg, suggesting saturable intestinal efflux transport [1]. Significant reductions in plasma HIV-1 RNA from baseline to day 11 were observed for all TAF dose groups compared with placebo (P < 0.01), with a median decrease of 1.08-1.73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg [2].. For the detailed information of GS-7340, the solubility of GS-7340 in water, the solubility of GS-7340 in DMSO, the solubility of GS-7340 in PBS buffer, the animal experiment (test) of GS-7340, the cell expriment (test) of GS-7340, the in vivo, in vitro and clinical trial test of GS-7340, the EC50, IC50,and affinity,of GS-7340, Please contact DC Chemicals.
For research and scientific purpose only, not for human use!
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate.
Product Name: Tenofovir Alafenamide Hemifumarate|Cat No. DC9294|cas: 1392275-56-7|Other names: Tenofovir alafenamide; GS7340; GS 7340| Molecule formular: C46H62N12O14P2Molecule Weight: 1068.4
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate.
IC50 value:
Target: NRTI; HIV reverse transcriptase inhibitor
GS-7340 reduces first-pass clearance to be an effective oral prodrug, its permeability and stability were characterized in vitro and detailed pharmacokinetic studies were completed in dogs. GS-7340 showed concentration-dependent permeability through monolayers of caco-2 cells and dose-dependent oral bioavailability in dogs, increasing from 1.7% at 2 mg/kg to 24.7% at 20 mg/kg, suggesting saturable intestinal efflux transport [1]. Significant reductions in plasma HIV-1 RNA from baseline to day 11 were observed for all TAF dose groups compared with placebo (P < 0.01), with a median decrease of 1.08-1.73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg [2].. For the detailed information of GS-7340, the solubility of GS-7340 in water, the solubility of GS-7340 in DMSO, the solubility of GS-7340 in PBS buffer, the animal experiment (test) of GS-7340, the cell expriment (test) of GS-7340, the in vivo, in vitro and clinical trial test of GS-7340, the EC50, IC50,and affinity,of GS-7340, Please contact DC Chemicals.
For research and scientific purpose only, not for human use!
MS023|CAS 1831110-54-3|DC Chemicals
MS023|CAS 1831110-54-3|DC Chemicals
MS023 is a potent, selective, and cell-active inhibitor of human type I PRMTs with IC50 of 4-119 nM.
Product Name: MS023|Cat No. DC9293|cas: 1831110-54-3|Other names: MS-023，MS 023| Molecule formular: C17H25N3OMolecule Weight: 287.4
MS023 potently inhibits PRMT1 (IC50 = 30 ± 9 nM), PRMT3 (IC50 = 119 ± 14 nM), PRMT4 (IC50 = 83 ± 10 nM), PRMT6 (IC50 = 4 ± 0.5 nM), and PRMT8 (IC50 = 5 ± 0.1 nM). Importantly, MS023 does not inhibit any type II PRMTs (PRMT5 and 9) and type III PRMT (PRMT7) at concentrations up to 10 μM. MS023 displays high potency for type I PRMTs including PRMT1, -3, -4, -6, and -8 but is completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases. MS023 potently decreases cellular levels of histone arginine asymmetric dimethylation. It also reduces global levels of arginine asymmetric dimethylation and concurrently increased levels of arginine monomethylation and symmetric dimethylation in cells.
MS023 is a potent, selective, and cell-active inhibitor of human type I PRMTs with IC50 of 4-119 nM.
Product Name: MS023|Cat No. DC9293|cas: 1831110-54-3|Other names: MS-023，MS 023| Molecule formular: C17H25N3OMolecule Weight: 287.4
MS023 potently inhibits PRMT1 (IC50 = 30 ± 9 nM), PRMT3 (IC50 = 119 ± 14 nM), PRMT4 (IC50 = 83 ± 10 nM), PRMT6 (IC50 = 4 ± 0.5 nM), and PRMT8 (IC50 = 5 ± 0.1 nM). Importantly, MS023 does not inhibit any type II PRMTs (PRMT5 and 9) and type III PRMT (PRMT7) at concentrations up to 10 μM. MS023 displays high potency for type I PRMTs including PRMT1, -3, -4, -6, and -8 but is completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases. MS023 potently decreases cellular levels of histone arginine asymmetric dimethylation. It also reduces global levels of arginine asymmetric dimethylation and concurrently increased levels of arginine monomethylation and symmetric dimethylation in cells.
CHIR-090|CAS 728865-23-4|DC Chemicals
CHIR-090|CAS 728865-23-4|DC Chemicals
CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.
Product Name: CHIR-090|Cat No. DC9292|cas: 728865-23-4|Other names: CHIR 090; CHIR090| Molecule formular: C24H27N3O5Molecule Weight: 437.49
CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.
CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.
Product Name: CHIR-090|Cat No. DC9292|cas: 728865-23-4|Other names: CHIR 090; CHIR090| Molecule formular: C24H27N3O5Molecule Weight: 437.49
CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.
SCH58261|CAS 160098-96-4|DC Chemicals
SCH58261|CAS 160098-96-4|DC Chemicals
SCH 58261 is a potent and selective A2a adenosine receptor antagonist with Ki of 2.3 nM and 2 nM for rat A2a and bovine A2a, respectively.
Cas: 160098-96-4
Product Name: SCH58261|Cat No. DC9284|cas: 160098-96-4|Other names: SCH-58261,SCH 58261| Molecule formular: C18H15N7OMolecule Weight: 345.36
SCH 58261 is a potent and selective A2a adenosine receptor antagonist with Ki of 2.3 nM and 2 nM for rat A2a and bovine A2a, respectively.
Cas: 160098-96-4
Product Name: SCH58261|Cat No. DC9284|cas: 160098-96-4|Other names: SCH-58261,SCH 58261| Molecule formular: C18H15N7OMolecule Weight: 345.36
Q-VD-Oph|CAS 1135695-98-5|DC Chemicals
Q-VD-Oph|CAS 1135695-98-5|DC Chemicals
Q-VD-Oph is a potent pan-caspase inhibitor with IC50 ranged from 25 to 400 nM for caspases 1,3,8, and 9.
Product Name: Q-VD-Oph|Cat No. DC9283|cas: 1135695-98-5|Other names: | Molecule formular: C26H25F2N3O6Molecule Weight: 513.49
Q-VD-Oph is a potent pan-caspase inhibitor with IC50 ranged from 25 to 400 nM for caspases 1,3,8, and 9.
Product Name: Q-VD-Oph|Cat No. DC9283|cas: 1135695-98-5|Other names: | Molecule formular: C26H25F2N3O6Molecule Weight: 513.49
1-NA-PP1|CAS 221243-82-9|DC Chemicals
1-NA-PP1|CAS 221243-82-9|DC Chemicals
1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).
Product Name: 1-NA-PP1|Cat No. DC9281|cas: 221243-82-9|Other names: 1-Naphthyl PP1| Molecule formular: C19H19N5Molecule Weight: 317.39
1-NA-PP1 was considerably more potent and showed distinct substituent effects at the pyrazolopyrimidine core. 1-NA-PP1 was cell-active, and potently blocked prostate cancer cell proliferation by inducing G2/M arrest. Overexpression of PKD1 or PKD3 almost completely reversed the growth arrest and the inhibition of tumor cell invasion caused by 1-NA-PP1, indicating that its anti-proliferative and anti-invasive activities were mediated through the inhibition of PKD. Interestingly, a 12-fold increase in sensitivity to 1-NA-PP1 could be achieved by engineering a gatekeeper mutation in the active site of PKD1, suggesting that 1-NA-PP1 could be paired with the analog-sensitive PKD1(M659G) for dissecting PKD-specific functions and signaling pathways in various biological systems.
1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).
Product Name: 1-NA-PP1|Cat No. DC9281|cas: 221243-82-9|Other names: 1-Naphthyl PP1| Molecule formular: C19H19N5Molecule Weight: 317.39
1-NA-PP1 was considerably more potent and showed distinct substituent effects at the pyrazolopyrimidine core. 1-NA-PP1 was cell-active, and potently blocked prostate cancer cell proliferation by inducing G2/M arrest. Overexpression of PKD1 or PKD3 almost completely reversed the growth arrest and the inhibition of tumor cell invasion caused by 1-NA-PP1, indicating that its anti-proliferative and anti-invasive activities were mediated through the inhibition of PKD. Interestingly, a 12-fold increase in sensitivity to 1-NA-PP1 could be achieved by engineering a gatekeeper mutation in the active site of PKD1, suggesting that 1-NA-PP1 could be paired with the analog-sensitive PKD1(M659G) for dissecting PKD-specific functions and signaling pathways in various biological systems.
PD-1/PD-L1 inhibitor 1|CAS 1675201-83-8|DC Chemicals
PD-1/PD-L1 inhibitor 1|CAS 1675201-83-8|DC Chemicals
PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor,IC50 values: 0.006 0.10 μM,a useful compound immunomodulator compound.
Product Name: PD-1/PD-L1 inhibitor 1|Cat No. DC9280|cas: 1675201-83-8|Other names: | Molecule formular: C29H33NO5Molecule Weight: 475.58
PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor,IC50 values: 0.006 0.10 μM,a useful compound immunomodulator compound.
PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor,IC50 values: 0.006 0.10 μM,a useful compound immunomodulator compound.
Product Name: PD-1/PD-L1 inhibitor 1|Cat No. DC9280|cas: 1675201-83-8|Other names: | Molecule formular: C29H33NO5Molecule Weight: 475.58
PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor,IC50 values: 0.006 0.10 μM,a useful compound immunomodulator compound.
MK-571|CAS 115103-85-0|DC Chemicals
MK-571|CAS 115103-85-0|DC Chemicals
MK-571 is a selective, orally active CysLT1 receptor antagonist.
Product Name: MK-571|Cat No. DC9279|cas: 115103-85-0|Other names: L-660,711，MK571，MK 571，L660711,L-660711| Molecule formular: C26H26ClN2O3S2NaMolecule Weight: 537.07
MK-571 has been reported to be a selective competitive inhibitor of [3H]leukrotriene D4 (LTD4) binding to CysLT1 receptors. LTD4 has been shown to induce contractions in guinea pig trachea and human lung membranes. Cysteinyl leukotrienes have also been identified as important pro-inflammatory mediators, therefore making MK-571 an anti-inflammatory agent. This compound demonstrates inhibitory characteristics of Mdr-1 (multidrug resistance protein-1) mediated transport. Additionally, studies suggest that this agent can augment the effects of cytotoxic agents on cells in vitro. MK-571 is an inhibitor of MRP1 and CysLT1 Receptor.
MK-571 is a selective, orally active CysLT1 receptor antagonist.
Product Name: MK-571|Cat No. DC9279|cas: 115103-85-0|Other names: L-660,711，MK571，MK 571，L660711,L-660711| Molecule formular: C26H26ClN2O3S2NaMolecule Weight: 537.07
MK-571 has been reported to be a selective competitive inhibitor of [3H]leukrotriene D4 (LTD4) binding to CysLT1 receptors. LTD4 has been shown to induce contractions in guinea pig trachea and human lung membranes. Cysteinyl leukotrienes have also been identified as important pro-inflammatory mediators, therefore making MK-571 an anti-inflammatory agent. This compound demonstrates inhibitory characteristics of Mdr-1 (multidrug resistance protein-1) mediated transport. Additionally, studies suggest that this agent can augment the effects of cytotoxic agents on cells in vitro. MK-571 is an inhibitor of MRP1 and CysLT1 Receptor.
CWHM-12|CAS 1564286-55-0|DC Chemicals
CWHM-12|CAS 1564286-55-0|DC Chemicals
CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1.
Product Name: CWHM-12|Cat No. DC9278|cas: 1564286-55-0|Other names: CWHM 12，CWHM12| Molecule formular: C26H32BrN5O6Molecule Weight: 590.47
CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1.in vitro: CWHM 12 demonstrated high potency against all of the five possible β subunit binding partners (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8) in in vitro ligand-binding assays, with somewhat less potency against αvβ5 than against the other αv integrins.
in vivo: Treated mice with CCl4 for 3 weeks to establish fibrotic disease and then treated with CWHM 12 or vehicle for the final 3 weeks of CCl4. CWHM12 significantly reduced liver fibrosis even after fibrotic disease had been established. Similar to our findings in the liver, administration of CWHM 12 significantly inhibited progression of pulmonary fibrosis.
CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1.
Product Name: CWHM-12|Cat No. DC9278|cas: 1564286-55-0|Other names: CWHM 12，CWHM12| Molecule formular: C26H32BrN5O6Molecule Weight: 590.47
CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1.in vitro: CWHM 12 demonstrated high potency against all of the five possible β subunit binding partners (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8) in in vitro ligand-binding assays, with somewhat less potency against αvβ5 than against the other αv integrins.
in vivo: Treated mice with CCl4 for 3 weeks to establish fibrotic disease and then treated with CWHM 12 or vehicle for the final 3 weeks of CCl4. CWHM12 significantly reduced liver fibrosis even after fibrotic disease had been established. Similar to our findings in the liver, administration of CWHM 12 significantly inhibited progression of pulmonary fibrosis.
C-DIM12|cas 178946-89-9 |DC Chemicals
C-DIM12|cas 178946-89-9 |DC Chemicals
C-DIM12 is a novel synthetic activator of Nurr1.
Product Name: C-DIM12|Cat No. DC9277|cas: 178946-89-9|Other names: | Molecule formular: C23H17ClN2Molecule Weight: 356.11
C-DIM12 is a novel synthetic activator of Nurr1. C-DIM12 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. C-DIM12 activates Nurr1 in cancer cells and prevents loss of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD in mice. C-DIM12 induced expression of Nurr1-regulated genes that was abolished by Nurr1 knockdown. C-DIM12 increased expression of transfected human Nurr1, induced Nurr1 protein expression in primary dopaminergic neurons and enhanced neuronal survival from exposure to 6-OHDA. C-DIM12 stimulates neuroprotective expression Nurr1-regulated genes in DA neurons.
C-DIM12 is a novel synthetic activator of Nurr1.
Product Name: C-DIM12|Cat No. DC9277|cas: 178946-89-9|Other names: | Molecule formular: C23H17ClN2Molecule Weight: 356.11
C-DIM12 is a novel synthetic activator of Nurr1. C-DIM12 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. C-DIM12 activates Nurr1 in cancer cells and prevents loss of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD in mice. C-DIM12 induced expression of Nurr1-regulated genes that was abolished by Nurr1 knockdown. C-DIM12 increased expression of transfected human Nurr1, induced Nurr1 protein expression in primary dopaminergic neurons and enhanced neuronal survival from exposure to 6-OHDA. C-DIM12 stimulates neuroprotective expression Nurr1-regulated genes in DA neurons.
KM 11060 |cas 774549-97-2|DC Chemicals
KM 11060 |cas 774549-97-2|DC Chemicals
KM 11060 corrects F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane (~75%) and Inhibits PDE5 activity.
Product Name: KM 11060|Cat No. DC9276|cas: 774549-97-2|Other names: KM11060,KM-11060| Molecule formular: C19H17Cl2N3O2SMolecule Weight: 422.33
KM 11060 corrects F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane (~75%) and Inhibits PDE5 activity.
KM 11060 corrects F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane (~75%) and Inhibits PDE5 activity.
Product Name: KM 11060|Cat No. DC9276|cas: 774549-97-2|Other names: KM11060,KM-11060| Molecule formular: C19H17Cl2N3O2SMolecule Weight: 422.33
KM 11060 corrects F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane (~75%) and Inhibits PDE5 activity.
Mirin |cas 1198097-97-0|DC Chemicals
Mirin |cas 1198097-97-0|DC Chemicals
Mirin is a Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11.
Product Name: Mirin|Cat No. DC9275|cas: 1198097-97-0|Other names: Mirin| Molecule formular: C10H8N2O2SMolecule Weight: 220.25
Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11. Prevents ATM activation in response to double strand breaks (IC50 = 12 μM) and induces G2 cell cycle arrest. Also blocks homology-directed repair in vitro.
Mirin is a Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11.
Product Name: Mirin|Cat No. DC9275|cas: 1198097-97-0|Other names: Mirin| Molecule formular: C10H8N2O2SMolecule Weight: 220.25
Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11. Prevents ATM activation in response to double strand breaks (IC50 = 12 μM) and induces G2 cell cycle arrest. Also blocks homology-directed repair in vitro.
YM 90709 |cas 163769-88-8|DC Chemicals
YM 90709 |cas 163769-88-8|DC Chemicals
YM 90709 has been reported to be a selective inhibitor of interleukin-5 (IL-5).
Product Name: YM 90709|Cat No. DC9274|cas: 163769-88-8|Other names: YM 90709,YM90709,YM-90709| Molecule formular: C22H21N3O2Molecule Weight: 359.42
YM 90709 has been reported to be a selective inhibitor of interleukin-5 (IL-5). This compound has been shown to inhibit IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects.
YM 90709 has been reported to be a selective inhibitor of interleukin-5 (IL-5).
Product Name: YM 90709|Cat No. DC9274|cas: 163769-88-8|Other names: YM 90709,YM90709,YM-90709| Molecule formular: C22H21N3O2Molecule Weight: 359.42
YM 90709 has been reported to be a selective inhibitor of interleukin-5 (IL-5). This compound has been shown to inhibit IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects.
SC-66 |cas 871361-88-5|DC Chemicals
SC-66 |cas 871361-88-5|DC Chemicals
SC-66 is an allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination.
Product Name: SC-66|Cat No. DC9273|cas: 871361-88-5|Other names: SC66,SC 66| Molecule formular: C18H16N2OMolecule Weight: 276.33
Allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination. Exhibits anticancer activity in vitro and in vivo.
SC-66 is an allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination.
Product Name: SC-66|Cat No. DC9273|cas: 871361-88-5|Other names: SC66,SC 66| Molecule formular: C18H16N2OMolecule Weight: 276.33
Allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination. Exhibits anticancer activity in vitro and in vivo.
K 858 |cas 72926-24-0|DC Chemicals
K 858 |cas 72926-24-0|DC Chemicals
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics.
Product Name: K 858|Cat No. DC9272|cas: 72926-24-0|Other names: K858,K-858| Molecule formular: C13H15N3O2SMolecule Weight: 277.34
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. Studies on HCT116 cells indicate that K 858 causes mitotic arrest, cell growth inhibition, and activates caspase-3. It is also believed that K858 inhibits the growth of cancer cells. Studies suggest that K 858 is not neurotoxic in motor coordination. Furthermore, K 858 can be a beneficial tool because unlike similar compounds that inhibit Eg5, K 858 does not form breaks in double stranded DNA.
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics.
Product Name: K 858|Cat No. DC9272|cas: 72926-24-0|Other names: K858,K-858| Molecule formular: C13H15N3O2SMolecule Weight: 277.34
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. Studies on HCT116 cells indicate that K 858 causes mitotic arrest, cell growth inhibition, and activates caspase-3. It is also believed that K858 inhibits the growth of cancer cells. Studies suggest that K 858 is not neurotoxic in motor coordination. Furthermore, K 858 can be a beneficial tool because unlike similar compounds that inhibit Eg5, K 858 does not form breaks in double stranded DNA.
JNJ-63533054|cas 1802326-66-4|DC Chemicals
JNJ-63533054|cas 1802326-66-4|DC Chemicals
JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.
Product Name: JNJ-63533054|Cat No. DC9271|cas: 1802326-66-4|Other names: JNJ 63533054,JNJ63533054| Molecule formular: C17H17ClN2O2Molecule Weight: 316.78
JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.
in vitro: JNJ-63533054 is a selective small-molecule agonist. JNJ-63533054 specifically activates human GPR139 in the calcium mobilization (EC50 = 16 ± 6 nM) and GTPγS binding (EC50 = 17 ± 4 nM) assays. JNJ-63533054 is found to be clean of any cross reactivity as judged by an external selectivity panel of 50 known GPCRs, ion channels, and transporters as well as our own internal whole cell lead generation biology selectivity panel.
in vivo: JNJ-63533054 is found to cross the blood-brain barrier and have good drug-like properties amenable for oral dosing in rat. JNJ-63533054 exhibits good stability in both human and rat microsomes and high solubility in aqueous media, and no DDI potential was found. [1] JNJ-63533054 also activates the rat and mouse GPR139 receptor with similar potency (rat EC50 = 63 ± 24 nM, mouse EC50 = 28 ± 7 nM).
JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.
Product Name: JNJ-63533054|Cat No. DC9271|cas: 1802326-66-4|Other names: JNJ 63533054,JNJ63533054| Molecule formular: C17H17ClN2O2Molecule Weight: 316.78
JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.
in vitro: JNJ-63533054 is a selective small-molecule agonist. JNJ-63533054 specifically activates human GPR139 in the calcium mobilization (EC50 = 16 ± 6 nM) and GTPγS binding (EC50 = 17 ± 4 nM) assays. JNJ-63533054 is found to be clean of any cross reactivity as judged by an external selectivity panel of 50 known GPCRs, ion channels, and transporters as well as our own internal whole cell lead generation biology selectivity panel.
in vivo: JNJ-63533054 is found to cross the blood-brain barrier and have good drug-like properties amenable for oral dosing in rat. JNJ-63533054 exhibits good stability in both human and rat microsomes and high solubility in aqueous media, and no DDI potential was found. [1] JNJ-63533054 also activates the rat and mouse GPR139 receptor with similar potency (rat EC50 = 63 ± 24 nM, mouse EC50 = 28 ± 7 nM).
Eg5 Inhibitor III（Dimethylenastron）|cas 863774-58-7|DC Chemicals
Eg5 Inhibitor III（Dimethylenastron）|cas 863774-58-7|DC Chemicals.
Eg5 Inhibitor III, Dimethylenastron is a cell-permeable quinazoline-thione compound that acts as a strong, specific, and reversible inhibitor of the microtubule-stimulated ATPase activity of the mitotic motor, Eg5.
Product Name: Eg5 Inhibitor III（Dimethylenastron）|Cat No. DC9270|cas: 863774-58-7|Other names: | Molecule formular: C16H18N2O2SMolecule Weight: 302.4
Eg5 Inhibitor III, Dimethylenastron is a cell-permeable quinazoline-thione compound that acts as a strong, specific, and reversible inhibitor of the microtubule-stimulated ATPase activity of the mitotic motor, Eg5. Eg5 Inhibitor III, Dimethylenastron shows little effect on the ATPase activity of kinesin-1, -4, -7 and -10. The compound also inhibits bipolar spindle formation in both HeLa cells and in Xenopus egg extracts and induces cell cycle arrest (~1 μM). Eg5 Inhibitor III, Dimethylenastron is shown to induce mitotic arrest, apoptosis and upregulate Hsp70 in human multiple myeloma cells.
Eg5 Inhibitor III, Dimethylenastron is a cell-permeable quinazoline-thione compound that acts as a strong, specific, and reversible inhibitor of the microtubule-stimulated ATPase activity of the mitotic motor, Eg5.
Product Name: Eg5 Inhibitor III（Dimethylenastron）|Cat No. DC9270|cas: 863774-58-7|Other names: | Molecule formular: C16H18N2O2SMolecule Weight: 302.4
Eg5 Inhibitor III, Dimethylenastron is a cell-permeable quinazoline-thione compound that acts as a strong, specific, and reversible inhibitor of the microtubule-stimulated ATPase activity of the mitotic motor, Eg5. Eg5 Inhibitor III, Dimethylenastron shows little effect on the ATPase activity of kinesin-1, -4, -7 and -10. The compound also inhibits bipolar spindle formation in both HeLa cells and in Xenopus egg extracts and induces cell cycle arrest (~1 μM). Eg5 Inhibitor III, Dimethylenastron is shown to induce mitotic arrest, apoptosis and upregulate Hsp70 in human multiple myeloma cells.
PRT4165|cas 31083-55-3|DC Chemicals
PRT4165|cas 31083-55-3|DC Chemicals
PRT4165 is a potent inhibitor of PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.
Product Name: PRT4165（NSC-600157）|Cat No. DC9269|cas: 31083-55-3|Other names: PRT 4165; PRT-4165; NSC600157; NSC-600157; NSC 600157| Molecule formular: C15H9NO2Molecule Weight: 235.24
PRT4165 is a potent inhibitor of PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.
in vitro: PRT4165 is a novel chromatin-remodeling compound and provide a new tool for the inhibition of ubiquitylation signaling at DNA double-strand breaks.PRT4165 inhibits histone H2A E3 ubiquitin ligase activity of RING1. PRT4165 Inhibits the E3 Ubiquitin Ligase Activity of PRC1. PRT4165 efficiently inhibits H2A ubiquitylation at lysine 119 (uH2AK119) and that this inhibition is dependent on both the concentration of PRT4165 and the incubation time with PRT4165. Treatment of cells for 60 min with 50 μm PRT4165 results in a dramatic reduction in total ubiquitylated histone H2A. PRT4165 inhibits the accumulation of all detectable ubiquitin at sites of DNA double-strand breaks (DSBs), the retention of several DNA damage response proteins in foci that form around DSBs, and the repair of the DSBs.
in vivo: PRT4165 inhibits the PRC1 E3 monoubiquitin ligase activity toward γ-H2AX.
PRT4165 is a potent inhibitor of PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.
Product Name: PRT4165（NSC-600157）|Cat No. DC9269|cas: 31083-55-3|Other names: PRT 4165; PRT-4165; NSC600157; NSC-600157; NSC 600157| Molecule formular: C15H9NO2Molecule Weight: 235.24
PRT4165 is a potent inhibitor of PRC1 (Polycomb-repressive complex 1)-mediated H2A ubiquitylation.
in vitro: PRT4165 is a novel chromatin-remodeling compound and provide a new tool for the inhibition of ubiquitylation signaling at DNA double-strand breaks.PRT4165 inhibits histone H2A E3 ubiquitin ligase activity of RING1. PRT4165 Inhibits the E3 Ubiquitin Ligase Activity of PRC1. PRT4165 efficiently inhibits H2A ubiquitylation at lysine 119 (uH2AK119) and that this inhibition is dependent on both the concentration of PRT4165 and the incubation time with PRT4165. Treatment of cells for 60 min with 50 μm PRT4165 results in a dramatic reduction in total ubiquitylated histone H2A. PRT4165 inhibits the accumulation of all detectable ubiquitin at sites of DNA double-strand breaks (DSBs), the retention of several DNA damage response proteins in foci that form around DSBs, and the repair of the DSBs.
in vivo: PRT4165 inhibits the PRC1 E3 monoubiquitin ligase activity toward γ-H2AX.
AZD9496|cas 1639042-08-2|DC Chemicals
AZD9496|cas 1639042-08-2|DC Chemicals
AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist.
Product Name: AZD9496|Cat No. DC9268|cas: 1639042-08-2|Other names: AZD-9496，AZD 9496| Molecule formular: C25H25F3N2O2Molecule Weight: 442.47
AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist.
AZD9496 can induce ERα degradation in breast cancer cell lines at picomolar concentrations. AZD9496 is curently under clinical trials. AZD9496 may be useful for the treatment of ER+ breast cancer.
AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist.
Product Name: AZD9496|Cat No. DC9268|cas: 1639042-08-2|Other names: AZD-9496，AZD 9496| Molecule formular: C25H25F3N2O2Molecule Weight: 442.47
AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist.
AZD9496 can induce ERα degradation in breast cancer cell lines at picomolar concentrations. AZD9496 is curently under clinical trials. AZD9496 may be useful for the treatment of ER+ breast cancer.
EPZ015866,EPZ-015866(GSK591)|PRMT5 inhibitor
EPZ015866,EPZ-015866(GSK591)|PRMT5 inhibitor
EPZ015866(GSK591) is a potent, selective PRMT5 inhibitor.
Product Name: EPZ015866(GSK591)|Cat No. DC9267|cas: 1616391-87-7|Other names: EPZ-015866,EPZ 015866，GSK-591,GSK 591,GSK3203591,GSK-3203591,GSK 3203591| Molecule formular: C22H28N4O2Molecule Weight: 380.22
In an in vitro biochemical assay, EPZ015866(GSK591) potently inhibits the PRMT5/MEP50 complex from methylating (histone) H4 with IC50 = 11 nM. In Z-138 cells, EPZ015866(GSK591) inhibits the symmetric arginine methylation of SmD3 with EC50 = 56 nM. Further, EPZ015866(GSK591) is selective for PRMT5 (up to 50 micromolar) relative to a panel of methyltransferases.
EPZ015866(GSK591) is a potent, selective PRMT5 inhibitor.
Product Name: EPZ015866(GSK591)|Cat No. DC9267|cas: 1616391-87-7|Other names: EPZ-015866,EPZ 015866，GSK-591,GSK 591,GSK3203591,GSK-3203591,GSK 3203591| Molecule formular: C22H28N4O2Molecule Weight: 380.22
In an in vitro biochemical assay, EPZ015866(GSK591) potently inhibits the PRMT5/MEP50 complex from methylating (histone) H4 with IC50 = 11 nM. In Z-138 cells, EPZ015866(GSK591) inhibits the symmetric arginine methylation of SmD3 with EC50 = 56 nM. Further, EPZ015866(GSK591) is selective for PRMT5 (up to 50 micromolar) relative to a panel of methyltransferases.
Cabozantinib S-malate|cas 1140909-48-3|DC Chemicals
Cabozantinib S-malate|cas 1140909-48-3|DC Chemicals
Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
Product Name: Cabozantinib S-malate|Cat No. DC9266|cas: 1140909-48-3|Other names: | Molecule formular: C32H30FN3O10Molecule Weight: 635.59
Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
in vitro: XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM [1]. XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth [2].
in vivo: XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively.
Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
Product Name: Cabozantinib S-malate|Cat No. DC9266|cas: 1140909-48-3|Other names: | Molecule formular: C32H30FN3O10Molecule Weight: 635.59
Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
in vitro: XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM [1]. XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth [2].
in vivo: XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively.
CP-640186|cas 591778-70-0|DC Chemicals
CP-640186|cas 591778-70-0|DC Chemicals
CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.
Product Name: CP-640186 hydrochloride|Cat No. DC9265|cas: 591778-70-0|Other names: | Molecule formular: C30H36ClN3O3Molecule Weight: 522.08
CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.
IC50 value: 53 nM/61 nM (rat liver ACC1/skeletal muscle ACC2)
in vitro: CP-640186, also inhibited both isozymes with IC50s of ~55 nM but was 2–3 times more potent than CP-610431 in inhibiting HepG2 cell fatty acid and TG synthesis. CP-640186 also stimulated fatty acid oxidation in C2C12 cells (ACC2) and in rat epitrochlearis muscle strips with EC50s of 57 nM and 1.3 uM.
in vivo: In rats, CP-640186 lowered hepatic, soleus muscle,quadriceps muscle, and cardiac muscle malonyl-CoA with ED50s of 55, 6, 15, and 8 mg/kg. Consequently, CP-640186 inhibited fatty acid synthesis in rats, CD1 mice,and ob/ob mice with ED50s of 13, 11, and 4 mg/kg, and stimulated rat whole body fatty acid oxidation with an
ED50 of ~30 mg/kg.
CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.
Product Name: CP-640186 hydrochloride|Cat No. DC9265|cas: 591778-70-0|Other names: | Molecule formular: C30H36ClN3O3Molecule Weight: 522.08
CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.
IC50 value: 53 nM/61 nM (rat liver ACC1/skeletal muscle ACC2)
in vitro: CP-640186, also inhibited both isozymes with IC50s of ~55 nM but was 2–3 times more potent than CP-610431 in inhibiting HepG2 cell fatty acid and TG synthesis. CP-640186 also stimulated fatty acid oxidation in C2C12 cells (ACC2) and in rat epitrochlearis muscle strips with EC50s of 57 nM and 1.3 uM.
in vivo: In rats, CP-640186 lowered hepatic, soleus muscle,quadriceps muscle, and cardiac muscle malonyl-CoA with ED50s of 55, 6, 15, and 8 mg/kg. Consequently, CP-640186 inhibited fatty acid synthesis in rats, CD1 mice,and ob/ob mice with ED50s of 13, 11, and 4 mg/kg, and stimulated rat whole body fatty acid oxidation with an
ED50 of ~30 mg/kg.
AZD3965|cas 1448671-31-5|DC Chemicals
AZD3965|cas 1448671-31-5|DC Chemicals
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
Product Name: AZD-3965|Cat No. DC9263|cas: 1448671-31-5|Other names: AZD-3965,AZD3965,AZD 3965| Molecule formular: C21H24F3N5O5SMolecule Weight: 515.51
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose and time dependent accumulation of lactate in the tumours, suppresses tumour growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine.The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers an novel mechanism for targeting the metabolic phenotype in tumours that preferentially express MCT1.
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
Product Name: AZD-3965|Cat No. DC9263|cas: 1448671-31-5|Other names: AZD-3965,AZD3965,AZD 3965| Molecule formular: C21H24F3N5O5SMolecule Weight: 515.51
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose and time dependent accumulation of lactate in the tumours, suppresses tumour growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine.The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers an novel mechanism for targeting the metabolic phenotype in tumours that preferentially express MCT1.
ABT-719|cas 162829-90-5|DC Chemicals
ABT-719|cas 162829-90-5|DC Chemicals
ABT-719 is a potent bacterial DNA gyrase inhibitor.
Product Name: ABT-719|Cat No. DC9262|cas: 162829-90-5|Other names: ABT-719,ABT 719,ABT719,A-86719.1| Molecule formular: C18H20FN3O3Molecule Weight: 345.37
ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy.
ABT-719 is a potent bacterial DNA gyrase inhibitor.
Product Name: ABT-719|Cat No. DC9262|cas: 162829-90-5|Other names: ABT-719,ABT 719,ABT719,A-86719.1| Molecule formular: C18H20FN3O3Molecule Weight: 345.37
ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy.
ABT-719|cas 162763-53-3|DC Chemicals
ABT-719|cas 162763-53-3|DC Chemicals
ABT-719 is a potent bacterial DNA gyrase inhibitor.
Product Name: ABT-719 HCl|Cat No. DC9261|cas: 162763-53-3|Other names: ABT-719,ABT 719,ABT719,A-86719.1| Molecule formular: C18H20FN3O3.HClMolecule Weight: 381.83
ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy.
ABT-719 is a potent bacterial DNA gyrase inhibitor.
Product Name: ABT-719 HCl|Cat No. DC9261|cas: 162763-53-3|Other names: ABT-719,ABT 719,ABT719,A-86719.1| Molecule formular: C18H20FN3O3.HClMolecule Weight: 381.83
ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy.
Eptapirone|cas 179756-85-5|DC Chemicals
Eptapirone|cas 179756-85-5|DC Chemicals
Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family.
Product Name: Eptapirone|Cat No. DC9260|cas: 179756-85-5|Other names: | Molecule formular: C16H23N7O2Molecule Weight: 345.4
Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family.Its affinity for the 5-HT1A receptor was reported to be 4.8 nM (Ki) (or 8.33 (pKi)), and its intrinsic activity approximately equal to that of serotonin (i.e., 100%).
Eptapirone and related high-efficacy 5-HT1A full and super agonists such as befiradol and F-15,599 were developed under the hypothesis that the maximum exploitable therapeutic benefits of 5-HT1A receptor agonists might not be able to be seen without the drugs employed possessing sufficiently high intrinsic activity at the receptor. As 5-HT1A receptor agonism, based on animal and other research, looked extremely promising for the treatment of depression from a theoretical perspective, this idea was developed as a potential explanation for the relatively modest clinical effectiveness seen with already available 5-HT1A receptor agonists like buspirone and tandospirone, which act merely as weak-to-moderate partial agonists of the receptor.
Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family.
Product Name: Eptapirone|Cat No. DC9260|cas: 179756-85-5|Other names: | Molecule formular: C16H23N7O2Molecule Weight: 345.4
Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family.Its affinity for the 5-HT1A receptor was reported to be 4.8 nM (Ki) (or 8.33 (pKi)), and its intrinsic activity approximately equal to that of serotonin (i.e., 100%).
Eptapirone and related high-efficacy 5-HT1A full and super agonists such as befiradol and F-15,599 were developed under the hypothesis that the maximum exploitable therapeutic benefits of 5-HT1A receptor agonists might not be able to be seen without the drugs employed possessing sufficiently high intrinsic activity at the receptor. As 5-HT1A receptor agonism, based on animal and other research, looked extremely promising for the treatment of depression from a theoretical perspective, this idea was developed as a potential explanation for the relatively modest clinical effectiveness seen with already available 5-HT1A receptor agonists like buspirone and tandospirone, which act merely as weak-to-moderate partial agonists of the receptor.
DAA1106|cas 220551-92-8|DC Chemicals
DAA1106|cas 220551-92-8|DC Chemicals
DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptors, in mitochondrial fractions of the rat brain.
Product Name: DAA1106|Cat No. DC9259|cas: 220551-92-8|Other names: DAA1106,DAA-1106,DAA 1106| Molecule formular: C23H22FNO4Molecule Weight: 395.42
DAA1106 bound to the mitochondrial fraction of the rat brain in a saturable manner. The dissociation constant (Kd) and maximal number of binding sites (Bmax) obtained from Scatchard plot analysis of the saturation curve of DAA1106 binding were 0.12 +/- 0.03 nM and 161.03 +/- 5.80 fmol/mg protein, respectively. DAA1106 binding to mitochondrial preparations of the rat cerebral cortex was inhibited by several peripheral benzodiapine receptor ligands, and DAA1106 was the most potent inhibitor in inhibiting DAA1106 binding among the peripheral benzodiazepine receptor ligands we tested. The binding of DAA1106 was not affected by several neurotransmitter-related compounds, including adrenoceptor, gamma-aminobutyric acid (GABA), dopamine, 5-hydroxytryptamine (5-HT), acetylcholine, histamine, glutamate and central benzodiazepine receptor ligands even at a concentration of 10 microM. In the cerebral cortex of rhesus monkeys, DAA1106 and 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3-isoquinoline carboxamide (PK11195) potently inhibited DAA1106 binding, while 7-chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydrobenzo[e][1,4]diazepin -2-one (Ro5-4864) did not. The highest DAA1106 binding was observed in the olfactory bulb, followed by the cerebellum. In autoradiographic studies, practically the same results were obtained, in that the highest binding of DAA1106 was in the olfactory bulb. Potent labeling was also noted in ventricular structures such as the choroid plexus. Thus, DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptors and should prove useful for elucidating the physiological relevance of events mediated through peripheral benzodiazepine receptors.
DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptors, in mitochondrial fractions of the rat brain.
Product Name: DAA1106|Cat No. DC9259|cas: 220551-92-8|Other names: DAA1106,DAA-1106,DAA 1106| Molecule formular: C23H22FNO4Molecule Weight: 395.42
DAA1106 bound to the mitochondrial fraction of the rat brain in a saturable manner. The dissociation constant (Kd) and maximal number of binding sites (Bmax) obtained from Scatchard plot analysis of the saturation curve of DAA1106 binding were 0.12 +/- 0.03 nM and 161.03 +/- 5.80 fmol/mg protein, respectively. DAA1106 binding to mitochondrial preparations of the rat cerebral cortex was inhibited by several peripheral benzodiapine receptor ligands, and DAA1106 was the most potent inhibitor in inhibiting DAA1106 binding among the peripheral benzodiazepine receptor ligands we tested. The binding of DAA1106 was not affected by several neurotransmitter-related compounds, including adrenoceptor, gamma-aminobutyric acid (GABA), dopamine, 5-hydroxytryptamine (5-HT), acetylcholine, histamine, glutamate and central benzodiazepine receptor ligands even at a concentration of 10 microM. In the cerebral cortex of rhesus monkeys, DAA1106 and 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3-isoquinoline carboxamide (PK11195) potently inhibited DAA1106 binding, while 7-chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydrobenzo[e][1,4]diazepin -2-one (Ro5-4864) did not. The highest DAA1106 binding was observed in the olfactory bulb, followed by the cerebellum. In autoradiographic studies, practically the same results were obtained, in that the highest binding of DAA1106 was in the olfactory bulb. Potent labeling was also noted in ventricular structures such as the choroid plexus. Thus, DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptors and should prove useful for elucidating the physiological relevance of events mediated through peripheral benzodiazepine receptors.
PD168393|cas 194423-15-9|DC Chemicals
PD168393|cas 194423-15-9|DC Chemicals
PD168393 is potent, cell-permeable, irreversible and selective inhibitor of EGF receptor (EGFR) tyrosine kinase and ErbB2.
Product Name: PD168393|Cat No. DC9258|cas: 194423-15-9|Other names: PD168393,PD-168393,PD 168393| Molecule formular: C17H13BrN4OMolecule Weight: 369.22
PD168393 is potent, cell-permeable, irreversible and selective inhibitor of EGF receptor (EGFR) tyrosine kinase and ErbB2. PD168393 has an IC50 value of 0.70 nM for EGFR, and is inactive against insulin, PDGFR, FGFR and PKC.
PD168393 is potent, cell-permeable, irreversible and selective inhibitor of EGF receptor (EGFR) tyrosine kinase and ErbB2.
Product Name: PD168393|Cat No. DC9258|cas: 194423-15-9|Other names: PD168393,PD-168393,PD 168393| Molecule formular: C17H13BrN4OMolecule Weight: 369.22
PD168393 is potent, cell-permeable, irreversible and selective inhibitor of EGF receptor (EGFR) tyrosine kinase and ErbB2. PD168393 has an IC50 value of 0.70 nM for EGFR, and is inactive against insulin, PDGFR, FGFR and PKC.
NSC59984|cas 803647-40-7|DC Chemicals
NSC59984|cas 803647-40-7|DC Chemicals
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
Product Name: NSC59984|Cat No. DC9257|cas: 803647-40-7|Other names: NSC-59984,NSC 59984| Molecule formular: C12H15N3O4Molecule Weight: 265.27
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
in vitro: NSC59984 specifically restores p53 pathway signaling in mutant p53-expressing human colorectal cancer cells. NSC59984 induces cell death in tumor cells but not normal cells with little or no genotoxicity. NSC59984 induces mutant p53 protein degradation through MDM2-mediated ubiquitination in cancer cells. NSC59984 restores p53 pathway signaling through activation of p73. NSC59984 induces p73-dependent cell apoptosis in cancer.
in vivo: NSC59984 synergizes with CPT11 to induce cell death in mutant p53-expressing colorectal cancer cells and inhibits mutant p53-associated colon tumor xenograft growth in a p73-dependent manner.
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
Product Name: NSC59984|Cat No. DC9257|cas: 803647-40-7|Other names: NSC-59984,NSC 59984| Molecule formular: C12H15N3O4Molecule Weight: 265.27
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
in vitro: NSC59984 specifically restores p53 pathway signaling in mutant p53-expressing human colorectal cancer cells. NSC59984 induces cell death in tumor cells but not normal cells with little or no genotoxicity. NSC59984 induces mutant p53 protein degradation through MDM2-mediated ubiquitination in cancer cells. NSC59984 restores p53 pathway signaling through activation of p73. NSC59984 induces p73-dependent cell apoptosis in cancer.
in vivo: NSC59984 synergizes with CPT11 to induce cell death in mutant p53-expressing colorectal cancer cells and inhibits mutant p53-associated colon tumor xenograft growth in a p73-dependent manner.
KS176|cas 1253452-78-6|DC Chemicals
KS176|cas 1253452-78-6|DC Chemicals
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.
Product Name: KS176|Cat No. DC9256|cas: 1253452-78-6|Other names: KS-176,KS 176| Molecule formular: C22H19N3O5Molecule Weight: 405.4
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.
Product Name: KS176|Cat No. DC9256|cas: 1253452-78-6|Other names: KS-176,KS 176| Molecule formular: C22H19N3O5Molecule Weight: 405.4
2016年5月22日星期日
VU0357017|cas 1135242-13-5|DC Chemicals
VU0357017|cas 1135242-13-5|DC Chemicals
VU0357017 hydrochloride is a highly selective M1 agonists that appear to act at an allosteric site to activate the receptor (EC50 = 477 ± 172 nM; pEC50 = 6.37 ± 0.15).
Product Name: VU0357017|Cat No. DC9255|cas: 1135242-13-5|Other names: VU0-357017,VU 0357017,CID-25010775; VU-0357017 hydrochloride; VU 0357017 hydrochloride| Molecule formular: C18H28ClN3O3Molecule Weight: 369.89
VU0357017 hydrochloride is a highly selective M1 agonists that appear to act at an allosteric site to activate the receptor (EC50 = 477 ± 172 nM; pEC50 = 6.37 ± 0.15).
in vitro: VU0357017 is a M1-selective agonists that appear to activate M1 through actions at an allosteric site. Ki values of VU0357017 derived from competition binding experiment is 9.91(rM1), 21.4 (rM2), 55.3 (rM3), 35 (rM4), and 50 (rM5), respectively. [1] VU0357017 is a potent and efficacious M1 agonist, selective versus M2?M5 family members and allosteric agonist. VU0357017 is a highly selective M1 agonist suggests that these compounds are unlikely to act at the highly conserved orthosteric site on M1 and are more likely to act as allosteric agonists.VU0357017 has robust effects on M1-activation of calcium mobilization and ERK1/2 phosphorylation but have little effect on β-arrestin recruitment. VU0357017 induces calcium release and ERK phosphorylation but is without effects on β-arrestin recruitment. VU0357017 significantly enhances threshold Θ-burst LTP and VU0364572 induces LTD at the Schaffer collateral-CA1 synapse of rodent hippocampal slices.
in vivo: VU0357017 has robust efficacy in improving hippocampal-dependent learning in rats. VU0357017 enhances performance in Morris water maze and contextual fear conditioning in rats.
VU0357017 hydrochloride is a highly selective M1 agonists that appear to act at an allosteric site to activate the receptor (EC50 = 477 ± 172 nM; pEC50 = 6.37 ± 0.15).
Product Name: VU0357017|Cat No. DC9255|cas: 1135242-13-5|Other names: VU0-357017,VU 0357017,CID-25010775; VU-0357017 hydrochloride; VU 0357017 hydrochloride| Molecule formular: C18H28ClN3O3Molecule Weight: 369.89
VU0357017 hydrochloride is a highly selective M1 agonists that appear to act at an allosteric site to activate the receptor (EC50 = 477 ± 172 nM; pEC50 = 6.37 ± 0.15).
in vitro: VU0357017 is a M1-selective agonists that appear to activate M1 through actions at an allosteric site. Ki values of VU0357017 derived from competition binding experiment is 9.91(rM1), 21.4 (rM2), 55.3 (rM3), 35 (rM4), and 50 (rM5), respectively. [1] VU0357017 is a potent and efficacious M1 agonist, selective versus M2?M5 family members and allosteric agonist. VU0357017 is a highly selective M1 agonist suggests that these compounds are unlikely to act at the highly conserved orthosteric site on M1 and are more likely to act as allosteric agonists.VU0357017 has robust effects on M1-activation of calcium mobilization and ERK1/2 phosphorylation but have little effect on β-arrestin recruitment. VU0357017 induces calcium release and ERK phosphorylation but is without effects on β-arrestin recruitment. VU0357017 significantly enhances threshold Θ-burst LTP and VU0364572 induces LTD at the Schaffer collateral-CA1 synapse of rodent hippocampal slices.
in vivo: VU0357017 has robust efficacy in improving hippocampal-dependent learning in rats. VU0357017 enhances performance in Morris water maze and contextual fear conditioning in rats.
Eliglustat hemitartrate|CAS 928659-70-5|Genz-99067
Eliglustat hemitartrate|CAS 928659-70-5|Genz-99067
Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.
Product Name: Eliglustat hemitartrate(Genz-99067)|Cat No. DC9291|cas: 928659-70-5|Other names: Genz-99067; Genz99067; Genz 99067| Molecule formular: C50H78N4O14Molecule Weight: 959.17
Eliglustat is a new promising substrate reduction therapy (SRT). [1] Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.
Eliglustat tartrate is a potent ceramide analog and has a selective inhibitory action on GLC synthase.
Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.
Product Name: Eliglustat hemitartrate(Genz-99067)|Cat No. DC9291|cas: 928659-70-5|Other names: Genz-99067; Genz99067; Genz 99067| Molecule formular: C50H78N4O14Molecule Weight: 959.17
Eliglustat is a new promising substrate reduction therapy (SRT). [1] Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.
Eliglustat tartrate is a potent ceramide analog and has a selective inhibitory action on GLC synthase.
Eliglustat|CAS 491833-29-5|Genz-99067
Eliglustat|CAS 491833-29-5|Genz-99067
Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.
Product Name: Eliglustat(Genz-99067)|Cat No. DC9290|cas: 491833-29-5|Other names: Genz-99067; Genz99067; Genz 99067| Molecule formular: C23H36N2O4Molecule Weight: 404.54
Eliglustat is a new promising substrate reduction therapy (SRT). [1] Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.
Eliglustat tartrate is a potent ceramide analog and has a selective inhibitory action on GLC synthase.
Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.
Product Name: Eliglustat(Genz-99067)|Cat No. DC9290|cas: 491833-29-5|Other names: Genz-99067; Genz99067; Genz 99067| Molecule formular: C23H36N2O4Molecule Weight: 404.54
Eliglustat is a new promising substrate reduction therapy (SRT). [1] Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.
Eliglustat tartrate is a potent ceramide analog and has a selective inhibitory action on GLC synthase.
UNC-2025|CAS 1429881-91-3(free base)|DC Chemicals
UNC-2025|CAS 1429881-91-3(free base)|DC Chemicals
UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
Cas: 1429881-91-3
Product Name: UNC-2025 HCl|Cat No. DC9289|cas: 1429881-91-3(free base)|Other names: UNC2025,UNC 2025| Molecule formular: C28H41ClN6OMolecule Weight: 513.12
UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
Cas: 1429881-91-3
Product Name: UNC-2025 HCl|Cat No. DC9289|cas: 1429881-91-3(free base)|Other names: UNC2025,UNC 2025| Molecule formular: C28H41ClN6OMolecule Weight: 513.12
D-Luciferin|CAS 2591-17-5|DC Chemicals
D-Luciferin|CAS 2591-17-5|DC Chemicals
D-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications.
Cas: 2591-17-5
Product Name: D-Luciferin|Cat No. DC9287|cas: 2591-17-5|Other names: | Molecule formular: C11H8N2O3S2Molecule Weight: 280.32
D-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications.
Cas: 2591-17-5
Product Name: D-Luciferin|Cat No. DC9287|cas: 2591-17-5|Other names: | Molecule formular: C11H8N2O3S2Molecule Weight: 280.32
K03861|CAS 853299-07-7|DC Chemicals
K03861|CAS 853299-07-7|DC Chemicals
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
Cas: 853299-07-7
Product Name: K03861|Cat No. DC9286|cas: 853299-07-7|Other names: K0-3861,K0 3861| Molecule formular: C24H26F3N7O2Molecule Weight: 501.50
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
Cas: 853299-07-7
Product Name: K03861|Cat No. DC9286|cas: 853299-07-7|Other names: K0-3861,K0 3861| Molecule formular: C24H26F3N7O2Molecule Weight: 501.50
GNF-7|CAS 839706-07-9|DC Chemicals
GNF-7|CAS 839706-07-9|DC Chemicals
GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively.
Cas: 839706-07-9
Product Name: GNF-7|Cat No. DC9285|cas: 839706-07-9|Other names: GNF7,GNF 7| Molecule formular: C28H24F3N7O2Molecule Weight: 547.53
GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively.
Cas: 839706-07-9
Product Name: GNF-7|Cat No. DC9285|cas: 839706-07-9|Other names: GNF7,GNF 7| Molecule formular: C28H24F3N7O2Molecule Weight: 547.53
MCC950 (CP-456773) sodium|cas 256373-96-3|DC Chemicals
MCC950 (CP-456773) sodium|cas 256373-96-3|DC Chemicals
MCC950 (CP-456773) sodium is a potent, selective, small-molecule inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs.
Product Name: MCC950 (CP-456773) sodium|Cat No. DC9254|cas: 256373-96-3|Other names: CP-456773 sodium; CRID3 sodium salt; MCC-950 sodium; CP456773 sodium; CRID-3 sodium salt| Molecule formular: C20H23N2NaO5SMolecule Weight: 426.46
MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes. MCC950 reduced interleukin-1β (IL-1β) production in vivo and attenuated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.
MCC950 (CP-456773) sodium is a potent, selective, small-molecule inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs.
Product Name: MCC950 (CP-456773) sodium|Cat No. DC9254|cas: 256373-96-3|Other names: CP-456773 sodium; CRID3 sodium salt; MCC-950 sodium; CP456773 sodium; CRID-3 sodium salt| Molecule formular: C20H23N2NaO5SMolecule Weight: 426.46
MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes. MCC950 reduced interleukin-1β (IL-1β) production in vivo and attenuated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.
ON123300|cas 1357470-29-1|DC Chemicals
ON123300|cas 1357470-29-1|DC Chemicals
ON123300 is a novel multiple kinase inhibitor.
Product Name: ON123300|Cat No. DC9253|cas: 1357470-29-1|Other names: ON 123300,ON-123300，ON123300| Molecule formular: C24H27N7OMolecule Weight: 429
ON123300 is a low molecular weight multikinase inhibitor identified through a series of screens that supported further analyses for brain tumor chemotherapy. Biochemical assays indicated that ON123300 was a strong inhibitor of Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as β-type platelet-derived growth factor receptor (PDGFRβ). ON123300 inhibited U87 glioma cell proliferation with an IC(50) 3.4 ± 0.1 μmol/L and reduced phosphorylation of Akt, yet it also unexpectedly induced Erk activation, both in a dose- and time-dependent manner that subsequently was attributed to relieving Akt-mediated C-Raf S259 inactivation and activating a p70S6K-initiated PI3K-negative feedback loop. Cotreatment with the EGFR inhibitor gefitinib produced synergistic cytotoxic effects. Pursuant to the in vitro studies, in vivo pharmacokinetic and pharmacodynamic studies of ON123300 were completed in mice bearing intracerebral U87 tumors following intravenous doses of 5 and 25 mg/kg alone, and also at the higher dose concurrently with gefitinib. ON123300 showed high brain and brain tumor accumulation based on brain partition coefficient values of at least 2.5. Consistent with the in vitro studies, single agent ON123300 caused a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors, whereas addition of gefitinib to the ON123300 regimen significantly enhanced p-Akt inhibition and prevented Erk activation. In summary, ON123300 demonstrated favorable pharmacokinetic characteristics, and future development for brain tumor therapy would require use of combinations, such as gefitinib, that mitigate its Erk activation and enhance its activity.
ON123300 is a novel multiple kinase inhibitor.
Product Name: ON123300|Cat No. DC9253|cas: 1357470-29-1|Other names: ON 123300,ON-123300，ON123300| Molecule formular: C24H27N7OMolecule Weight: 429
ON123300 is a low molecular weight multikinase inhibitor identified through a series of screens that supported further analyses for brain tumor chemotherapy. Biochemical assays indicated that ON123300 was a strong inhibitor of Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as β-type platelet-derived growth factor receptor (PDGFRβ). ON123300 inhibited U87 glioma cell proliferation with an IC(50) 3.4 ± 0.1 μmol/L and reduced phosphorylation of Akt, yet it also unexpectedly induced Erk activation, both in a dose- and time-dependent manner that subsequently was attributed to relieving Akt-mediated C-Raf S259 inactivation and activating a p70S6K-initiated PI3K-negative feedback loop. Cotreatment with the EGFR inhibitor gefitinib produced synergistic cytotoxic effects. Pursuant to the in vitro studies, in vivo pharmacokinetic and pharmacodynamic studies of ON123300 were completed in mice bearing intracerebral U87 tumors following intravenous doses of 5 and 25 mg/kg alone, and also at the higher dose concurrently with gefitinib. ON123300 showed high brain and brain tumor accumulation based on brain partition coefficient values of at least 2.5. Consistent with the in vitro studies, single agent ON123300 caused a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors, whereas addition of gefitinib to the ON123300 regimen significantly enhanced p-Akt inhibition and prevented Erk activation. In summary, ON123300 demonstrated favorable pharmacokinetic characteristics, and future development for brain tumor therapy would require use of combinations, such as gefitinib, that mitigate its Erk activation and enhance its activity.
Tretinoin|cas 302-79-4|DC Chemicals
Tretinoin|cas 302-79-4|DC Chemicals
Product Name: Tretinoin|Cat No. DC9241|cas: 302-79-4|Other names: | Molecule formular: C20H28O2Molecule Weight: 300.44
For research only, not for human use!
Product Name: Tretinoin|Cat No. DC9241|cas: 302-79-4|Other names: | Molecule formular: C20H28O2Molecule Weight: 300.44
For research only, not for human use!
PS-47|cas 1180676-33-8|DC Chemicals
PS-47|cas 1180676-33-8|DC Chemicals
Product Name: PS-47|Cat No. DC9240|cas: 1180676-33-8|Other names: | Molecule formular: C17H15ClO2Molecule Weight: 286.75
For research only, not for human use!
Product Name: PS-47|Cat No. DC9240|cas: 1180676-33-8|Other names: | Molecule formular: C17H15ClO2Molecule Weight: 286.75
For research only, not for human use!
Lipstatin|cas 96829-59-3|DC Chemicals
Lipstatin|cas 96829-59-3|DC Chemicals
Product Name: Lipstatin|Cat No. DC9239|cas: 96829-59-3|Other names: | Molecule formular: C29H49NO5Molecule Weight: 491.71
For research only, not for human use!
Product Name: Lipstatin|Cat No. DC9239|cas: 96829-59-3|Other names: | Molecule formular: C29H49NO5Molecule Weight: 491.71
For research only, not for human use!
Sancycline|cas 808-26-4|DC Chemicals
Sancycline|cas 808-26-4|DC Chemicals
Product Name: Sancycline|Cat No. DC9238|cas: 808-26-4|Other names: | Molecule formular: C21H22N2O7Molecule Weight: 414.41
For research only, not for human use!
Product Name: Sancycline|Cat No. DC9238|cas: 808-26-4|Other names: | Molecule formular: C21H22N2O7Molecule Weight: 414.41
For research only, not for human use!
Glatiramer acetate|cas 147245-92-9|DC Chemicals
Glatiramer acetate|cas 147245-92-9|DC Chemicals
Product Name: Glatiramer acetate|Cat No. DC9237|cas: 147245-92-9|Other names: | Molecule formular: C25H45N5O13Molecule Weight: 623.65
For research only, not for human use!
Product Name: Glatiramer acetate|Cat No. DC9237|cas: 147245-92-9|Other names: | Molecule formular: C25H45N5O13Molecule Weight: 623.65
For research only, not for human use!
Brequinar|cas 96187-53-0|DC Chemicals
Brequinar|cas 96187-53-0|DC Chemicals.
Product Name: Brequinar|Cat No. DC9236|cas: 96187-53-0|Other names: | Molecule formular: C22H13F2NO2Molecule Weight: 361.34
For research only, not for human use!
Product Name: Brequinar|Cat No. DC9236|cas: 96187-53-0|Other names: | Molecule formular: C22H13F2NO2Molecule Weight: 361.34
For research only, not for human use!
Succinimidyl Myristate|cas 69888-86-4|DC Chemicals
Succinimidyl Myristate|cas 69888-86-4|DC Chemicals
Product Name: Succinimidyl Myristate|Cat No. DC9235|cas: 69888-86-4|Other names: | Molecule formular: C18H31NO4Molecule Weight: 325.44
For research only, not for human use!
Product Name: Succinimidyl Myristate|Cat No. DC9235|cas: 69888-86-4|Other names: | Molecule formular: C18H31NO4Molecule Weight: 325.44
For research only, not for human use!
Diphenyleneiodonium Chloride|cas 4673-26-1|DC Chemicals
Diphenyleneiodonium Chloride|cas 4673-26-1|DC Chemicals
Product Name: Diphenyleneiodonium Chloride|Cat No. DC9234|cas: 4673-26-1|Other names: | Molecule formular: C12H8ClIMolecule Weight: 314.55
For research only, not for human use!
Product Name: Diphenyleneiodonium Chloride|Cat No. DC9234|cas: 4673-26-1|Other names: | Molecule formular: C12H8ClIMolecule Weight: 314.55
For research only, not for human use!
Retinal|cas 116-31-4|DC Chemicals
Retinal|cas 116-31-4|DC Chemicals
Product Name: Retinal|Cat No. DC9233|cas: 116-31-4|Other names: | Molecule formular: C20H28OMolecule Weight: 284.44
For research only, not for human use!
Product Name: Retinal|Cat No. DC9233|cas: 116-31-4|Other names: | Molecule formular: C20H28OMolecule Weight: 284.44
For research only, not for human use!
BMS-791325 hydrochloride|cas 958002-36-3|DC Chemicals
BMS-791325 hydrochloride|cas 958002-36-3|DC Chemicals
Product Name: BMS-791325 hydrochloride|Cat No. DC9232|cas: 958002-36-3|Other names: | Molecule formular: C36H45N5O5S.HClMolecule Weight: 696.30
For research only, not for human use!
Product Name: BMS-791325 hydrochloride|Cat No. DC9232|cas: 958002-36-3|Other names: | Molecule formular: C36H45N5O5S.HClMolecule Weight: 696.30
For research only, not for human use!
Pirenzepine hydrochloride|cas 29868-97-1|DC Chemicals
Pirenzepine hydrochloride|cas 29868-97-1|DC Chemicals
Product Name: Pirenzepine hydrochloride|Cat No. DC9231|cas: 29868-97-1|Other names: | Molecule formular: C19H23Cl2N5O2Molecule Weight: 424.32
For research only, not for human use!
Product Name: Pirenzepine hydrochloride|Cat No. DC9231|cas: 29868-97-1|Other names: | Molecule formular: C19H23Cl2N5O2Molecule Weight: 424.32
For research only, not for human use!
OSI420|cas 183321-86-0|DC Chemicals
OSI420|cas 183321-86-0|DC Chemicals
Product Name: OSI420|Cat No. DC9230|cas: 183321-86-0|Other names: | Molecule formular: C21H21N3O4Molecule Weight: 379.41
For research only, not for human use!
Product Name: OSI420|Cat No. DC9230|cas: 183321-86-0|Other names: | Molecule formular: C21H21N3O4Molecule Weight: 379.41
For research only, not for human use!
Poloxamer 188|cas 9003-11-6|DC Chemicals
Poloxamer 188|cas 9003-11-6|DC Chemicals
Product Name: Poloxamer 188|Cat No. DC9229|cas: 9003-11-6|Other names: | Molecule formular: C5H10O2Molecule Weight: 102.13
For research only, not for human use!
Product Name: Poloxamer 188|Cat No. DC9229|cas: 9003-11-6|Other names: | Molecule formular: C5H10O2Molecule Weight: 102.13
For research only, not for human use!
Quinfamide|cas 62265-68-3|DC Chemicals
Quinfamide|cas 62265-68-3|DC Chemicals
Product Name: Quinfamide|Cat No. DC9228|cas: 62265-68-3|Other names: | Molecule formular: C16H13Cl2NO4Molecule Weight: 354.18
For research only, not for human use!
Product Name: Quinfamide|Cat No. DC9228|cas: 62265-68-3|Other names: | Molecule formular: C16H13Cl2NO4Molecule Weight: 354.18
For research only, not for human use!
Fluazuron|cas 86811-58-7|DC Chemicals
Fluazuron|cas 86811-58-7|DC Chemicals
Product Name: Fluazuron|Cat No. DC9227|cas: 86811-58-7|Other names: | Molecule formular: C20H10Cl2F5N3O3Molecule Weight: 506.21
For research only, not for human use!
Product Name: Fluazuron|Cat No. DC9227|cas: 86811-58-7|Other names: | Molecule formular: C20H10Cl2F5N3O3Molecule Weight: 506.21
For research only, not for human use!
Propiverine HCl|cas 54556-98-8|DC Chemicals
Propiverine HCl|cas 54556-98-8|DC Chemicals
Product Name: Propiverine HCl|Cat No. DC9226|cas: 54556-98-8|Other names: | Molecule formular: C23H30ClNO3Molecule Weight: 403.94
For research only, not for human use!
Product Name: Propiverine HCl|Cat No. DC9226|cas: 54556-98-8|Other names: | Molecule formular: C23H30ClNO3Molecule Weight: 403.94
For research only, not for human use!
Pentedrone|cas 879669-95-1|DC Chemicals
Pentedrone|cas 879669-95-1|DC Chemicals
Product Name: Pentedrone|Cat No. DC9225|cas: 879669-95-1|Other names: | Molecule formular: C12H18ClNOMolecule Weight: 227.73
For research only, not for human use!
Product Name: Pentedrone|Cat No. DC9225|cas: 879669-95-1|Other names: | Molecule formular: C12H18ClNOMolecule Weight: 227.73
For research only, not for human use!
PCI-6|cas 181289-33-8|DC Chemicals
PCI-6|cas 181289-33-8|DC Chemicals
Product Name: PCI-6|Cat No. DC9224|cas: 181289-33-8|Other names: | Molecule formular: C9H17NO3Molecule Weight: 187.24
For research only, not for human use!
Product Name: PCI-6|Cat No. DC9224|cas: 181289-33-8|Other names: | Molecule formular: C9H17NO3Molecule Weight: 187.24
For research only, not for human use!
Dihydro Silodosin|cas 175870-21-0|DC Chemicals
Dihydro Silodosin|cas 175870-21-0|DC Chemicals
Product Name: Dihydro Silodosin|Cat No. DC9223|cas: 175870-21-0|Other names: | Molecule formular: C25H30F3N3O4Molecule Weight: 493.52
For research only, not for human use!
Product Name: Dihydro Silodosin|Cat No. DC9223|cas: 175870-21-0|Other names: | Molecule formular: C25H30F3N3O4Molecule Weight: 493.52
For research only, not for human use!
A967079 |cas 1170613-55-4|DC Chemicals
A967079 |cas 1170613-55-4|DC Chemicals
Product Name: A967079|Cat No. DC9222|cas: 1170613-55-4|Other names: | Molecule formular: C12H14FNOMolecule Weight: 207.24
For research only, not for human use!
Product Name: A967079|Cat No. DC9222|cas: 1170613-55-4|Other names: | Molecule formular: C12H14FNOMolecule Weight: 207.24
For research only, not for human use!
Cefatrizine|cas 51627-14-6|DC Chemicals
Cefatrizine|cas 51627-14-6|DC Chemicals
Product Name: Cefatrizine|Cat No. DC9221|cas: 51627-14-6|Other names: | Molecule formular: C18H18N6O5S2Molecule Weight: 462.51
For research only, not for human use!
Product Name: Cefatrizine|Cat No. DC9221|cas: 51627-14-6|Other names: | Molecule formular: C18H18N6O5S2Molecule Weight: 462.51
For research only, not for human use!
1-Kestose|cas 470-69-9|DC Chemicals
1-Kestose|cas 470-69-9|DC Chemicals
Product Name: 1-Kestose|Cat No. DC9220|cas: 470-69-9|Other names: | Molecule formular: C19H34O16Molecule Weight: 518.46
For research only, not for human use!.
Product Name: 1-Kestose|Cat No. DC9220|cas: 470-69-9|Other names: | Molecule formular: C19H34O16Molecule Weight: 518.46
For research only, not for human use!.
Sarsasapogenin|cas 82597-74-8|DC Chemicals
Sarsasapogenin|cas 82597-74-8|DC Chemicals
Product Name: Sarsasapogenin|Cat No. DC9215|cas: 82597-74-8|Other names: | Molecule formular: C27H44O3Molecule Weight: 416.64
For research only, not for human use!
Product Name: Sarsasapogenin|Cat No. DC9215|cas: 82597-74-8|Other names: | Molecule formular: C27H44O3Molecule Weight: 416.64
For research only, not for human use!
Solifenacin|cas 242478-37-1|DC Chemicals
Solifenacin|cas 242478-37-1|DC Chemicals
Product Name: Solifenacin|Cat No. DC9214|cas: 242478-37-1|Other names: | Molecule formular: C23H26N2O2Molecule Weight: 362.47
For research only, not for human use!
Product Name: Solifenacin|Cat No. DC9214|cas: 242478-37-1|Other names: | Molecule formular: C23H26N2O2Molecule Weight: 362.47
For research only, not for human use!
GBR12783|cas 67469-57-2|DC Chemicals
GBR12783|cas 67469-57-2|DC Chemicals
Product Name: GBR12783|Cat No. DC9213|cas: 67469-57-2|Other names: | Molecule formular: C28H34Cl2N2OMolecule Weight: 485.49
For research only, not for human use!
Product Name: GBR12783|Cat No. DC9213|cas: 67469-57-2|Other names: | Molecule formular: C28H34Cl2N2OMolecule Weight: 485.49
For research only, not for human use!
Furafylline|cas 80288-49-9|DC Chemicals
Furafylline|cas 80288-49-9|DC Chemicals
Product Name: Furafylline|Cat No. DC9212|cas: 80288-49-9|Other names: | Molecule formular: C12H12N4O3Molecule Weight: 260.25
For research only, not for human use!
Product Name: Furafylline|Cat No. DC9212|cas: 80288-49-9|Other names: | Molecule formular: C12H12N4O3Molecule Weight: 260.25
For research only, not for human use!
GAMITHROMYCIN|cas 145435-72-9|DC Chemicals
GAMITHROMYCIN|cas 145435-72-9|DC Chemicals
Product Name: GAMITHROMYCIN|Cat No. DC9211|cas: 145435-72-9|Other names: | Molecule formular: C40H76N2O12Molecule Weight: 777.04
For research only, not for human use!
Product Name: GAMITHROMYCIN|Cat No. DC9211|cas: 145435-72-9|Other names: | Molecule formular: C40H76N2O12Molecule Weight: 777.04
For research only, not for human use!
Ormetoprim|cas 6981-18-6|DC Chemicals
Ormetoprim|cas 6981-18-6|DC Chemicals
Product Name: Ormetoprim|Cat No. DC9210|cas: 6981-18-6|Other names: | Molecule formular: C14H18N4O2Molecule Weight: 274.32
For research only, not for human use!
Product Name: Ormetoprim|Cat No. DC9210|cas: 6981-18-6|Other names: | Molecule formular: C14H18N4O2Molecule Weight: 274.32
For research only, not for human use!
Carbazeran|cas 70724-25-3|DC Chemicals
Carbazeran|cas 70724-25-3|DC Chemicals
Product Name: Carbazeran|Cat No. DC9209|cas: 70724-25-3|Other names: | Molecule formular: C18H24N4O4Molecule Weight: 360.41
For research only, not for human use!
Product Name: Carbazeran|Cat No. DC9209|cas: 70724-25-3|Other names: | Molecule formular: C18H24N4O4Molecule Weight: 360.41
For research only, not for human use!
Cetaben|cas 55986-43-1|DC Chemicals
Cetaben|cas 55986-43-1|DC Chemicals
Product Name: Cetaben|Cat No. DC9208|cas: 55986-43-1|Other names: | Molecule formular: C23H39NO2Molecule Weight: 361.56
For research only, not for human use!
Product Name: Cetaben|Cat No. DC9208|cas: 55986-43-1|Other names: | Molecule formular: C23H39NO2Molecule Weight: 361.56
For research only, not for human use!
BMS-207147/Ravuconazole|cas 182760-06-1|DC Chemicals
BMS-207147/Ravuconazole|cas 182760-06-1|DC Chemicals
Product Name: BMS-207147/Ravuconazole|Cat No. DC9207|cas: 182760-06-1|Other names: | Molecule formular: C22H17F2N5OSMolecule Weight: 437.46
For research only, not for human use!
Product Name: BMS-207147/Ravuconazole|Cat No. DC9207|cas: 182760-06-1|Other names: | Molecule formular: C22H17F2N5OSMolecule Weight: 437.46
For research only, not for human use!
Cysteamine bitartrate|cas 27761-19-9|DC Chemicals
Cysteamine bitartrate|cas 27761-19-9|DC Chemicals
Product Name: Cysteamine bitartrate|Cat No. DC9206|cas: 27761-19-9|Other names: | Molecule formular: C6H13NO6SMolecule Weight: 227.24
For research only, not for human use!
Product Name: Cysteamine bitartrate|Cat No. DC9206|cas: 27761-19-9|Other names: | Molecule formular: C6H13NO6SMolecule Weight: 227.24
For research only, not for human use!
Pteroic acid|cas 119-24-4|DC Chemicals
Pteroic acid|cas 119-24-4|DC Chemicals
Product Name: Pteroic acid|Cat No. DC9204|cas: 119-24-4|Other names: | Molecule formular: C14H12N6O3Molecule Weight: 312.28
For research only, not for human use!
Product Name: Pteroic acid|Cat No. DC9204|cas: 119-24-4|Other names: | Molecule formular: C14H12N6O3Molecule Weight: 312.28
For research only, not for human use!
Gadopentetate dimeglumine|cas 86050-77-3|DC Chemicals
Gadopentetate dimeglumine|cas 86050-77-3|DC Chemicals
Product Name: Gadopentetate dimeglumine|Cat No. DC9203|cas: 86050-77-3|Other names: | Molecule formular: C14H20GdN3O10.2C7H17NO5Molecule Weight: 938
For research only, not for human use!
Product Name: Gadopentetate dimeglumine|Cat No. DC9203|cas: 86050-77-3|Other names: | Molecule formular: C14H20GdN3O10.2C7H17NO5Molecule Weight: 938
For research only, not for human use!
Colamine phosphate|cas 1071-23-4|DC Chemicals
Colamine phosphate|cas 1071-23-4|DC Chemicals
Product Name: Colamine phosphate|Cat No. DC9202|cas: 1071-23-4|Other names: | Molecule formular: C2H8NO4PMolecule Weight: 141.06
For research only, not for human use!
Product Name: Colamine phosphate|Cat No. DC9202|cas: 1071-23-4|Other names: | Molecule formular: C2H8NO4PMolecule Weight: 141.06
For research only, not for human use!
MK-5172|MK5172,cas 1206524-85-7|DC Chemicals
MK-5172|MK5172,cas 1206524-85-7|DC Chemicals
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
Product Name: Grazoprevir(MK-5172)|Cat No. DC9201|cas: 1206524-85-7|Other names: MK 5172; MK5172| Molecule formular: C38H50N6O9SMolecule Weight: 766.9
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system [1]
Target: HCV NS3/4a protease
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a.
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1].
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1. For the detailed information of MK-5172, the solubility of MK-5172 in water, the solubility of MK-5172 in DMSO, the solubility of MK-5172 in PBS buffer, the animal experiment (test) of MK-5172, the cell expriment (test) of MK-5172, the in vivo, in vitro and clinical trial test of MK-5172, the EC50, IC50,and affinity,of MK-5172, Please contact DC Chemicals.
For research and scientific purpose only, not for human use!
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
Product Name: Grazoprevir(MK-5172)|Cat No. DC9201|cas: 1206524-85-7|Other names: MK 5172; MK5172| Molecule formular: C38H50N6O9SMolecule Weight: 766.9
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system [1]
Target: HCV NS3/4a protease
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a.
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1].
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1. For the detailed information of MK-5172, the solubility of MK-5172 in water, the solubility of MK-5172 in DMSO, the solubility of MK-5172 in PBS buffer, the animal experiment (test) of MK-5172, the cell expriment (test) of MK-5172, the in vivo, in vitro and clinical trial test of MK-5172, the EC50, IC50,and affinity,of MK-5172, Please contact DC Chemicals.
For research and scientific purpose only, not for human use!
SCE 2174|cas 95789-30-3|DC Chemicals
SCE 2174|cas 95789-30-3|DC Chemicals
Product Name: SCE 2174|Cat No. DC9200|cas: 95789-30-3|Other names: | Molecule formular: C27H37N9O7S3.2ClHMolecule Weight: 768.765
For research only, not for human use!
Product Name: SCE 2174|Cat No. DC9200|cas: 95789-30-3|Other names: | Molecule formular: C27H37N9O7S3.2ClHMolecule Weight: 768.765
For research only, not for human use!
Erythromycin A Oxime|cas 111321-02-9|DC Chemicals
Erythromycin A Oxime|cas 111321-02-9|DC Chemicals
Product Name: Erythromycin A Oxime|Cat No. DC9199|cas: 111321-02-9|Other names: | Molecule formular: C37H68N2O13Molecule Weight: 748.94
For research only, not for human use!
Product Name: Erythromycin A Oxime|Cat No. DC9199|cas: 111321-02-9|Other names: | Molecule formular: C37H68N2O13Molecule Weight: 748.94
For research only, not for human use!
Atopaxar(E5555)|cas 751475-53-3|DC Chemicals
Atopaxar(E5555)|cas 751475-53-3|DC Chemicals
Product Name: Atopaxar(E5555)|Cat No. DC9198|cas: 751475-53-3|Other names: | Molecule formular: C29H38FN3O5Molecule Weight: 527.63
For research only, not for human use!
Product Name: Atopaxar(E5555)|Cat No. DC9198|cas: 751475-53-3|Other names: | Molecule formular: C29H38FN3O5Molecule Weight: 527.63
For research only, not for human use!
Cefepime|cas 88040-23-7|DC Chemicals
Cefepime|cas 88040-23-7|DC Chemicals
Product Name: Cefepime|Cat No. DC9197|cas: 88040-23-7|Other names: | Molecule formular: C19H24N6O5S2Molecule Weight: 480.56
For research only, not for human use!
Product Name: Cefepime|Cat No. DC9197|cas: 88040-23-7|Other names: | Molecule formular: C19H24N6O5S2Molecule Weight: 480.56
For research only, not for human use!
confidorsl|cas 138261-41-3|DC Chemicals
confidorsl|cas 138261-41-3|DC Chemicals
Product Name: confidorsl|Cat No. DC9196|cas: 138261-41-3|Other names: | Molecule formular: C9H10ClN5O2Molecule Weight: 255.66
For research only, not for human use!
Product Name: confidorsl|Cat No. DC9196|cas: 138261-41-3|Other names: | Molecule formular: C9H10ClN5O2Molecule Weight: 255.66
For research only, not for human use!
Conivaptan|cas 210101-16-9|DC Chemicals
Conivaptan|cas 210101-16-9|DC Chemicals
Product Name: Conivaptan|Cat No. DC9195|cas: 210101-16-9|Other names: | Molecule formular: C32H26N4O2Molecule Weight: 498.58
For research only, not for human use!
Product Name: Conivaptan|Cat No. DC9195|cas: 210101-16-9|Other names: | Molecule formular: C32H26N4O2Molecule Weight: 498.58
For research only, not for human use!
Lactose|cas 63-42-3|DC Chemicals
Lactose|cas 63-42-3|DC Chemicals
>98%,Standard References
Product Name: Lactose|Cat No. DCZ-283|cas: 63-42-3|Other names: | Molecule formular: C12H22O11Molecule Weight: 342.3
For research only, not for human use!
>98%,Standard References
Product Name: Lactose|Cat No. DCZ-283|cas: 63-42-3|Other names: | Molecule formular: C12H22O11Molecule Weight: 342.3
For research only, not for human use!
Tritetradecanoin|cas 555-45-3|DC Chemicals
Tritetradecanoin|cas 555-45-3|DC Chemicals
>98%,Standard References
Product Name: Tritetradecanoin|Cat No. DCZ-282|cas: 555-45-3|Other names: | Molecule formular: C45H86O6Molecule Weight: 723.16
For research only, not for human use!
>98%,Standard References
Product Name: Tritetradecanoin|Cat No. DCZ-282|cas: 555-45-3|Other names: | Molecule formular: C45H86O6Molecule Weight: 723.16
For research only, not for human use!
Sodium Demethylcantharidate|cas 13114-29-9|DC Chemicals
Sodium Demethylcantharidate|cas 13114-29-9|DC Chemicals
>98%,Standard References
Product Name: Sodium Demethylcantharidate|Cat No. DCZ-280|cas: 13114-29-9|Other names: | Molecule formular: Molecule Weight:
For research only, not for human use!
>98%,Standard References
Product Name: Sodium Demethylcantharidate|Cat No. DCZ-280|cas: 13114-29-9|Other names: | Molecule formular: Molecule Weight:
For research only, not for human use!
4-Hydroxyisoleucine|cas 55399-93-4|DC Chemicals
4-Hydroxyisoleucine|cas 55399-93-4|DC Chemicals
>98%,Standard References
Product Name: 4-Hydroxyisoleucine|Cat No. DCZ-279|cas: 55399-93-4|Other names: | Molecule formular: C6H13NO3Molecule Weight: 147.17
For research only, not for human use!
>98%,Standard References
Product Name: 4-Hydroxyisoleucine|Cat No. DCZ-279|cas: 55399-93-4|Other names: | Molecule formular: C6H13NO3Molecule Weight: 147.17
For research only, not for human use!
BMS687453|CAS 1000998-59-3|DC Chemicals
BMS687453|CAS 1000998-59-3|DC Chemicals
BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.
Product Name: BMS-687453|Cat No. DC9252|cas: 1000998-59-3|Other names: BMS-687453，BMS687453，BMS 687453| Molecule formular: C22H21ClN2O6Molecule Weight: 444.865
BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays. Similar potencies and selectivity were also observed in the full length receptor co-transfection assays. BMS687453 has negligible cross-reactivity against a panel of human nuclear hormone receptors including PPARδ. BMS687453 demonstrated an excellent pharmacological and safety profile in preclinical studies and thus was chosen as a development candidate for the treatment of atherosclerosis and dyslipidemia.
BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.
Product Name: BMS-687453|Cat No. DC9252|cas: 1000998-59-3|Other names: BMS-687453，BMS687453，BMS 687453| Molecule formular: C22H21ClN2O6Molecule Weight: 444.865
BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays. Similar potencies and selectivity were also observed in the full length receptor co-transfection assays. BMS687453 has negligible cross-reactivity against a panel of human nuclear hormone receptors including PPARδ. BMS687453 demonstrated an excellent pharmacological and safety profile in preclinical studies and thus was chosen as a development candidate for the treatment of atherosclerosis and dyslipidemia.
RS-102895 hydrochloride|CAS 1173022-16-6|DC Chemicals
RS-102895 hydrochloride|CAS 1173022-16-6|DC Chemicals
RS 102895 hydrochloride is a chemokine receptor CCR2 antagonist.
Product Name: RS-102895 hydrochloride|Cat No. DC9251|cas: 1173022-16-6|Other names: RS-102895，RS 102895，RS102895| Molecule formular: C21H21F3N2O2.HClMolecule Weight: 426.86
RS 102895 Hydrochloride is a CKR-2B (CCR2)-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 μM for inhibition of human recombinant CKR-2B and CKR-1 (CCR2b and CCR1 receptors) respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 μM respectively. Inhibits α1A-AR, α1D-AR and SR-1A (α1A, α1D and 5-HT1A receptors).
RS 102895 hydrochloride is a chemokine receptor CCR2 antagonist.
Product Name: RS-102895 hydrochloride|Cat No. DC9251|cas: 1173022-16-6|Other names: RS-102895，RS 102895，RS102895| Molecule formular: C21H21F3N2O2.HClMolecule Weight: 426.86
RS 102895 Hydrochloride is a CKR-2B (CCR2)-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 μM for inhibition of human recombinant CKR-2B and CKR-1 (CCR2b and CCR1 receptors) respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 μM respectively. Inhibits α1A-AR, α1D-AR and SR-1A (α1A, α1D and 5-HT1A receptors).
DL-AP7|CAS 78966-69-5|DC Chemicals
DL-AP7|CAS 78966-69-5|DC Chemicals
DL-AP7 is a competitive antagonist of the ionotropic glutamate receptor, NMDA.
Product Name: DL-AP7|Cat No. DC9250|cas: 78966-69-5|Other names: | Molecule formular: C7H16NO5PMolecule Weight: 225.2
DL-AP7 is a competitive antagonist of the ionotropic glutamate receptor, NMDA. Studies indicate that the S1 and S2 domains of the NMDA receptor are essential in DL-AP7 and other related antagonists to bind to the receptor. In addition, the positively charged Lys residues at the second interaction site and Arg at the fourth site are key factors in ligand binding. The NMDA receptor is unique in that it requires binding of two ligands, glutamate and glycine to become activated. As a result of its inhibitory affects, DL-AP7 is an ideal tool in studying signaling pathways and ion flow through the NMDA receptor.
DL-AP7 is a competitive antagonist of the ionotropic glutamate receptor, NMDA.
Product Name: DL-AP7|Cat No. DC9250|cas: 78966-69-5|Other names: | Molecule formular: C7H16NO5PMolecule Weight: 225.2
DL-AP7 is a competitive antagonist of the ionotropic glutamate receptor, NMDA. Studies indicate that the S1 and S2 domains of the NMDA receptor are essential in DL-AP7 and other related antagonists to bind to the receptor. In addition, the positively charged Lys residues at the second interaction site and Arg at the fourth site are key factors in ligand binding. The NMDA receptor is unique in that it requires binding of two ligands, glutamate and glycine to become activated. As a result of its inhibitory affects, DL-AP7 is an ideal tool in studying signaling pathways and ion flow through the NMDA receptor.
3-Cyano-7-ethoxycoumarin|CAS 869477-96-3|CYP1A1 &1A2 substrate
3-Cyano-7-ethoxycoumarin|CAS 869477-96-3|CYP1A1 &1A2 substrate
3-Cyano-7-ethoxycoumarin is a fluorescent P450 substrate (excitation/emission wavelengths = 408/455 nm); metabolized to cyano-hydroxycoumarin.
Product Name: 3-Cyano-7-ethoxycoumarin|Cat No. DC9249|cas: 117620-77-6|Other names: | Molecule formular: C12H9NO3Molecule Weight: 215.2
3-Cyano-7-ethoxycoumarin is a fluorescent P450 substrate (excitation/emission wavelengths = 408/455 nm); metabolized to cyano-hydroxycoumarin.
Product Name: 3-Cyano-7-ethoxycoumarin|Cat No. DC9249|cas: 117620-77-6|Other names: | Molecule formular: C12H9NO3Molecule Weight: 215.2
Olodaterol|CAS 869477-96-3| DC Chemicals
Olodaterol|CAS 869477-96-3| DC Chemicals
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.
Product Name: Olodaterol(BI-1744) hydrochloride|Cat No. DC9248|cas: 869477-96-3|Other names: BI-1744,BI 1744,BI1744| Molecule formular: C21H26N2O5.HClMolecule Weight: 422.9
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.
Product Name: Olodaterol(BI-1744) hydrochloride|Cat No. DC9248|cas: 869477-96-3|Other names: BI-1744,BI 1744,BI1744| Molecule formular: C21H26N2O5.HClMolecule Weight: 422.9
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
AP-III-a4(ENOblock) hydrochloride|DC Chemicals
AP-III-a4(ENOblock) hydrochloride|DC Chemicals
ENOblock Hcl(AP-III-a4 Hcl) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.
Product Name: AP-III-a4(ENOblock) hydrochloride|Cat No. DC9247|cas: 1177827-73-4(free base)|Other names: | Molecule formular: C31H44ClFN8O3Molecule Weight: 631.18
ENOblock Hcl(AP-III-a4 Hcl) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.
Product Name: AP-III-a4(ENOblock) hydrochloride|Cat No. DC9247|cas: 1177827-73-4(free base)|Other names: | Molecule formular: C31H44ClFN8O3Molecule Weight: 631.18
TECTOCHRYSIN|CAS 520-28-5|DC Chemicals
TECTOCHRYSIN|CAS 520-28-5|DC Chemicals
purity >98%,Standard References
Product Name: TECTOCHRYSIN|Cat No. DCZ-292|cas: 520-28-5|Other names: | Molecule formular: C16H12O4Molecule Weight: 268.26
purity >98%,Standard References
Product Name: TECTOCHRYSIN|Cat No. DCZ-292|cas: 520-28-5|Other names: | Molecule formular: C16H12O4Molecule Weight: 268.26
isorhapontigenin|CAS 32507-66-7|DC Chemicals
isorhapontigenin|CAS 32507-66-7|DC Chemicals
purity >98%,Standard References
Product Name: isorhapontigenin|Cat No. DCZ-291|cas: 32507-66-7|Other names: | Molecule formular: C15H14O4Molecule Weight: 258.27
purity >98%,Standard References
Product Name: isorhapontigenin|Cat No. DCZ-291|cas: 32507-66-7|Other names: | Molecule formular: C15H14O4Molecule Weight: 258.27
Isobavachin|CAS 31524-62-6|DC Chemicals
Isobavachin|CAS 31524-62-6|DC Chemicals
purity >98%,Standard References
Product Name: Isobavachin|Cat No. DCZ-290|cas: 31524-62-6|Other names: | Molecule formular: C20H20O4Molecule Weight: 324.37
purity >98%,Standard References
Product Name: Isobavachin|Cat No. DCZ-290|cas: 31524-62-6|Other names: | Molecule formular: C20H20O4Molecule Weight: 324.37
songorine|CAS 509-24-0|DC Chemicals
songorine|CAS 509-24-0|DC Chemicals
purity >98%,Standard References
Product Name: songorine|Cat No. DCZ-289|cas: 509-24-0|Other names: | Molecule formular: C22H31NO3Molecule Weight: 357.491
purity >98%,Standard References
Product Name: songorine|Cat No. DCZ-289|cas: 509-24-0|Other names: | Molecule formular: C22H31NO3Molecule Weight: 357.491
ISOVITEXIN|CAS 38953-85-4|DC Chemicals
ISOVITEXIN|CAS 38953-85-4|DC Chemicals
purity >98%,Standard References
Product Name: ISOVITEXIN|Cat No. DCZ-288|cas: 38953-85-4|Other names: | Molecule formular: C21H20O10Molecule Weight: 432.38
purity >98%,Standard References
Product Name: ISOVITEXIN|Cat No. DCZ-288|cas: 38953-85-4|Other names: | Molecule formular: C21H20O10Molecule Weight: 432.38
Protopine|CAS 130-86-9|DC Chemicals
Protopine|CAS 130-86-9|DC Chemicals
purity >98%,Standard References
Product Name: Protopine|Cat No. DCZ-287|cas: 130-86-9|Other names: | Molecule formular: 130-86-9Molecule Weight: 353.37
purity >98%,Standard References
Product Name: Protopine|Cat No. DCZ-287|cas: 130-86-9|Other names: | Molecule formular: 130-86-9Molecule Weight: 353.37
8-GERANOPSORALEN|CAS 7437-55-0|DC Chemicals
8-GERANOPSORALEN|CAS 7437-55-0|DC Chemicals
purity >98%,Standard References
Product Name: 8-GERANOPSORALEN|Cat No. DCZ-286|cas: 7437-55-0|Other names: | Molecule formular: C21H22O4Molecule Weight: 338.4
purity >98%,Standard References
Product Name: 8-GERANOPSORALEN|Cat No. DCZ-286|cas: 7437-55-0|Other names: | Molecule formular: C21H22O4Molecule Weight: 338.4
Vitamin E|CAS 59-02-9|DC Chemicals
Vitamin E|CAS 59-02-9|DC Chemicals
purity >98%,Standard References
Product Name: Vitamin E|Cat No. DCZ-285|cas: 59-02-9|Other names: | Molecule formular: C29H50O2Molecule Weight: 430.71
purity >98%,Standard References
Product Name: Vitamin E|Cat No. DCZ-285|cas: 59-02-9|Other names: | Molecule formular: C29H50O2Molecule Weight: 430.71
S1RA HCl|cas 1265917-14-3|DC Chemicals
S1RA HCl|cas 1265917-14-3|DC Chemicals
S1RA(E-52862) is a potent and selective sigma-1 receptor(σ1R, Ki=17 nM), showed good selectivity against σ2R (Ki > 1000 nM).
Product Name: S1RA hydrochloride|Cat No. DC9264|cas: 1265917-14-3|Other names: E-52862; E52862; E 52862| Molecule formular: C20H24ClN3O2Molecule Weight: 373.88
S1RA, E-52862, or 4-(2-((5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)oxy)ethyl)morpholine is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 17.0 ± 7.0 nM, selective over the sigma-2 receptor and against a panel of other 170 receptors, enzymes, transporters and ion channels.[1][2] In preclinical studies, S1RA has demonstrated efficacy in relieving neuropathic pain and pain in other sensitizing conditions, associated with an improvement of the emotional negative state.For the detailed information of S1RA, the solubility of S1RA in water, the solubility of S1RA in DMSO, the solubility of S1RA in PBS buffer, the animal experiment (test) of S1RA, the cell expriment (test) of S1RA, the in vivo, in vitro and clinical trial test of S1RA, the EC50, IC50,and Affinity of S1RA, Please contact DC Chemicals.
For research only, not for human use.
S1RA(E-52862) is a potent and selective sigma-1 receptor(σ1R, Ki=17 nM), showed good selectivity against σ2R (Ki > 1000 nM).
Product Name: S1RA hydrochloride|Cat No. DC9264|cas: 1265917-14-3|Other names: E-52862; E52862; E 52862| Molecule formular: C20H24ClN3O2Molecule Weight: 373.88
S1RA, E-52862, or 4-(2-((5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)oxy)ethyl)morpholine is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 17.0 ± 7.0 nM, selective over the sigma-2 receptor and against a panel of other 170 receptors, enzymes, transporters and ion channels.[1][2] In preclinical studies, S1RA has demonstrated efficacy in relieving neuropathic pain and pain in other sensitizing conditions, associated with an improvement of the emotional negative state.For the detailed information of S1RA, the solubility of S1RA in water, the solubility of S1RA in DMSO, the solubility of S1RA in PBS buffer, the animal experiment (test) of S1RA, the cell expriment (test) of S1RA, the in vivo, in vitro and clinical trial test of S1RA, the EC50, IC50,and Affinity of S1RA, Please contact DC Chemicals.
For research only, not for human use.
Allasecurinine|DC Chemicals
Allasecurinine|DC Chemicals
purity >98%,Standard References
Product Name: Allasecurinine|Cat No. DCZ-284|cas: N/A|Other names: | Molecule formular: C13H15NO2Molecule Weight: 217.26.
For research only, not for human use!
purity >98%,Standard References
Product Name: Allasecurinine|Cat No. DCZ-284|cas: N/A|Other names: | Molecule formular: C13H15NO2Molecule Weight: 217.26.
For research only, not for human use!
PJ34(free base)|cas 344458-19-1|DC Chemicals
PJ34(free base)|cas 344458-19-1|DC Chemicals
Product Name: PJ34(free base)|Cat No. DC9246|cas: 344458-19-1|Other names: | Molecule formular: C17H17N3O2Molecule Weight: 295.34
For research only, not for human use!
Product Name: PJ34(free base)|Cat No. DC9246|cas: 344458-19-1|Other names: | Molecule formular: C17H17N3O2Molecule Weight: 295.34
For research only, not for human use!
LDE-225 HCl||DC Chemicals
LDE-225 HCl||DC Chemicals
Product Name: LDE-225 HCl|Cat No. DC9245|cas: N/A|Other names: LDE225,NVP-LDE 225| Molecule formular: C26H26F3N3O3.HClMolecule Weight: 521.96
For research only, not for human use!
Product Name: LDE-225 HCl|Cat No. DC9245|cas: N/A|Other names: LDE225,NVP-LDE 225| Molecule formular: C26H26F3N3O3.HClMolecule Weight: 521.96
For research only, not for human use!
LX-1606|cas 1033805-22-9|DC Chemicals
LX-1606|cas 1033805-22-9|DC Chemicals
Product Name: LX-1606|Cat No. DC9244|cas: 1033805-22-9|Other names: | Molecule formular: C27H26ClF3N6O3Molecule Weight: 574.98
For research only, not for human use!
Product Name: LX-1606|Cat No. DC9244|cas: 1033805-22-9|Other names: | Molecule formular: C27H26ClF3N6O3Molecule Weight: 574.98
For research only, not for human use!
LP533401 HCl|cas 1040526-12-2|DC Chemicals
LP533401 HCl|cas 1040526-12-2|DC Chemicals
Product Name: LP533401 HCl|Cat No. DC9243|cas: 1040526-12-2|Other names: | Molecule formular: C27H23ClF4N4O3Molecule Weight: 562.94.
For research only, not for human use!
Product Name: LP533401 HCl|Cat No. DC9243|cas: 1040526-12-2|Other names: | Molecule formular: C27H23ClF4N4O3Molecule Weight: 562.94.
For research only, not for human use!
Imatinib(free base)|cas 152459-95-5|DC Chemicals
Imatinib(free base)|cas 152459-95-5|DC Chemicals
Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
Product Name: Imatinib(free base)|Cat No. DC9242|cas: 152459-95-5|Other names: | Molecule formular: C29H31N7OMolecule Weight: 493.6
Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
For research only, not for human use!
Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
Product Name: Imatinib(free base)|Cat No. DC9242|cas: 152459-95-5|Other names: | Molecule formular: C29H31N7OMolecule Weight: 493.6
Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
For research only, not for human use!
Maoecrystal A|cas 96850-30-5|DC Chemicals
Maoecrystal A|cas 96850-30-5|DC Chemicals
>98%,Standard References
Product Name: Maoecrystal A|Cat No. DCZ-266|cas: 96850-30-5|Other names: | Molecule formular: C22H28O6Molecule Weight: 388.45
For research only, not for human use!
>98%,Standard References
Product Name: Maoecrystal A|Cat No. DCZ-266|cas: 96850-30-5|Other names: | Molecule formular: C22H28O6Molecule Weight: 388.45
For research only, not for human use!
Rosmarinic acid|cas 80225-53-2|DC Chemicals
Rosmarinic acid|cas 80225-53-2|DC Chemicals
>98%,Standard References
Product Name: Rosmarinic acid|Cat No. DCZ-265|cas: 80225-53-2|Other names: | Molecule formular: C20H26O5Molecule Weight: 346.42
For research only, not for human use!
>98%,Standard References
Product Name: Rosmarinic acid|Cat No. DCZ-265|cas: 80225-53-2|Other names: | Molecule formular: C20H26O5Molecule Weight: 346.42
For research only, not for human use!
Loganin|cas 18524-94-2|DC Chemicals
Loganin|cas 18524-94-2|DC Chemicals
>98%,Standard References
Product Name: Loganin|Cat No. DCZ-264|cas: 18524-94-2|Other names: | Molecule formular: C17H26O10Molecule Weight: 390.38
For research only, not for human use!
>98%,Standard References
Product Name: Loganin|Cat No. DCZ-264|cas: 18524-94-2|Other names: | Molecule formular: C17H26O10Molecule Weight: 390.38
For research only, not for human use!
Ophiopogonin D|cas 41753-55-3|DC Chemicals
Ophiopogonin D|cas 41753-55-3|DC Chemicals
>98%,Standard References
Product Name: Ophiopogonin D|Cat No. DCZ-263|cas: 41753-55-3|Other names: | Molecule formular: C44H70O16Molecule Weight: 855.02.
For research only, not for human use!
>98%,Standard References
Product Name: Ophiopogonin D|Cat No. DCZ-263|cas: 41753-55-3|Other names: | Molecule formular: C44H70O16Molecule Weight: 855.02.
For research only, not for human use!
Oroxin A|cas 57396-78-8|DC Chemicals
Oroxin A|cas 57396-78-8|DC Chemicals
>98%,Standard References
Product Name: Oroxin A|Cat No. DCZ-262|cas: 57396-78-8|Other names: | Molecule formular: C21H20O10Molecule Weight: 432.38
For research only, not for human use!
>98%,Standard References
Product Name: Oroxin A|Cat No. DCZ-262|cas: 57396-78-8|Other names: | Molecule formular: C21H20O10Molecule Weight: 432.38
For research only, not for human use!
2016年5月20日星期五
Ganoderic acid C6|cas 105742-76-5|DC Chemicals
Ganoderic acid C6|cas 105742-76-5|DC Chemicals
>98%,Standard References
Product Name: Ganoderic acid C6|Cat No. DCZ-261|cas: 105742-76-5|Other names: | Molecule formular: Molecule Weight:
For research only, not for human use!
>98%,Standard References
Product Name: Ganoderic acid C6|Cat No. DCZ-261|cas: 105742-76-5|Other names: | Molecule formular: Molecule Weight:
For research only, not for human use!
Atropine sulfate monohydrate|cas 5908-99-6|DC Chemicals
Atropine sulfate monohydrate|cas 5908-99-6|DC Chemicals
>98%,Standard References
Product Name: Atropine sulfate monohydrate|Cat No. DCZ-260|cas: 5908-99-6|Other names: | Molecule formular: C34H50N2O11SMolecule Weight: 694.83
For research only, not for human use!
>98%,Standard References
Product Name: Atropine sulfate monohydrate|Cat No. DCZ-260|cas: 5908-99-6|Other names: | Molecule formular: C34H50N2O11SMolecule Weight: 694.83
For research only, not for human use!
2,5-Dihydroxybenzoic acid|cas 490-79-9|DC Chemicals
2,5-Dihydroxybenzoic acid|cas 490-79-9|DC Chemicals
>98%,Standard References
Product Name: 2,5-Dihydroxybenzoic acid|Cat No. DCZ-259|cas: 490-79-9|Other names: | Molecule formular: C7H6O4Molecule Weight: 154.12
For research only, not for human use!
>98%,Standard References
Product Name: 2,5-Dihydroxybenzoic acid|Cat No. DCZ-259|cas: 490-79-9|Other names: | Molecule formular: C7H6O4Molecule Weight: 154.12
For research only, not for human use!
Borneol|cas 6627-72-1|DC Chemicals
Borneol|cas 6627-72-1|DC Chemicals
>98%,Standard References
Product Name: Borneol|Cat No. DCZ-258|cas: 6627-72-1|Other names: | Molecule formular: C10H18OMolecule Weight: 154.25
For research only, not for human use!
>98%,Standard References
Product Name: Borneol|Cat No. DCZ-258|cas: 6627-72-1|Other names: | Molecule formular: C10H18OMolecule Weight: 154.25
For research only, not for human use!
D-Glucosamine sulfate|cas 29031-19-4|DC Chemicals
D-Glucosamine sulfate|cas 29031-19-4|DC Chemicals
>98%,Standard References
Product Name: D-Glucosamine sulfate|Cat No. DCZ-257|cas: 29031-19-4|Other names: | Molecule formular: C6H15NO9SMolecule Weight: 277.25
For research only, not for human use!
>98%,Standard References
Product Name: D-Glucosamine sulfate|Cat No. DCZ-257|cas: 29031-19-4|Other names: | Molecule formular: C6H15NO9SMolecule Weight: 277.25
For research only, not for human use!
Liensinine perchlorate|cas 2385-63-9|DC Chemicals
Liensinine perchlorate|cas 2385-63-9|DC Chemicals
>98%,Standard References
Product Name: Liensinine perchlorate|Cat No. DCZ-256|cas: 2385-63-9|Other names: | Molecule formular: C37H42N2O6.ClHO4Molecule Weight: 711.20
For research only, not for human use!
>98%,Standard References
Product Name: Liensinine perchlorate|Cat No. DCZ-256|cas: 2385-63-9|Other names: | Molecule formular: C37H42N2O6.ClHO4Molecule Weight: 711.20
For research only, not for human use!
Corynoxine B|cas 17391-18-3|DC Chemicals
Corynoxine B|cas 17391-18-3|DC Chemicals
>98%,Standard References
Product Name: Corynoxine B|Cat No. DCZ-255|cas: 17391-18-3|Other names: | Molecule formular: C22H28N2O4Molecule Weight: 384.47
For research only, not for human use!
>98%,Standard References
Product Name: Corynoxine B|Cat No. DCZ-255|cas: 17391-18-3|Other names: | Molecule formular: C22H28N2O4Molecule Weight: 384.47
For research only, not for human use!
Picfeltarraenin IB|cas 97230-46-1|DC Chemicals
Picfeltarraenin IB|cas 97230-46-1|DC Chemicals
>98%,Standard References
Product Name: Picfeltarraenin IB|Cat No. DCZ-254|cas: 97230-46-1|Other names: | Molecule formular: C42H64O14Molecule Weight: 792.95
For research only, not for human use!
>98%,Standard References
Product Name: Picfeltarraenin IB|Cat No. DCZ-254|cas: 97230-46-1|Other names: | Molecule formular: C42H64O14Molecule Weight: 792.95
For research only, not for human use!
Gypenoside A|cas 157752-01-7|DC Chemicals
Gypenoside A|cas 157752-01-7|DC Chemicals
>98%,Standard References
Product Name: Gypenoside A|Cat No. DCZ-253|cas: 157752-01-7|Other names: | Molecule formular: Molecule Weight:
For research only, not for human use!
>98%,Standard References
Product Name: Gypenoside A|Cat No. DCZ-253|cas: 157752-01-7|Other names: | Molecule formular: Molecule Weight:
For research only, not for human use!
订阅：
博文 (Atom)